<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Arch Toxicol</journal-id><journal-id journal-id-type="iso-abbrev">Arch Toxicol</journal-id><journal-id journal-id-type="pmc-domain-id">365</journal-id><journal-id journal-id-type="pmc-domain">springeropen</journal-id><journal-title-group><journal-title>Archives of Toxicology</journal-title></journal-title-group><issn pub-type="ppub">0340-5761</issn><issn pub-type="epub">1432-0738</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Springer</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12085399</article-id><article-id pub-id-type="pmcid-ver">PMC12085399.1</article-id><article-id pub-id-type="pmcaid">12085399</article-id><article-id pub-id-type="pmcaiid">12085399</article-id><article-id pub-id-type="pmid">40178592</article-id><article-id pub-id-type="doi">10.1007/s00204-025-03992-7</article-id><article-id pub-id-type="publisher-id">3992</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Toxicokinetics and Metabolism</subject></subj-group></article-categories><title-group><article-title>Quantitative in vitro-to-in vivo extrapolation of human adrenergic and trace amine-associated receptor 1 potencies of pre-workout supplement ingredients using physiologically based kinetic modelling-based reverse dosimetry</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0009-0006-6879-5243</contrib-id><name name-style="western"><surname>Pinckaers</surname><given-names initials="NET">Nicole E. T.</given-names></name><address><email>n.pinckaers@maastrichtuniversity.nl</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Blankesteijn</surname><given-names initials="WM">W. Matthijs</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mircheva</surname><given-names initials="A">Anastasiya</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Punt</surname><given-names initials="A">Ans</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Opperhuizen</surname><given-names initials="A">Antoon</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>van Schooten</surname><given-names initials="FJ">Frederik-Jan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Vrolijk</surname><given-names initials="M">Misha</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02jz4aj89</institution-id><institution-id institution-id-type="GRID">grid.5012.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 0481 6099</institution-id><institution>Department of Pharmacology and Toxicology, </institution><institution>Maastricht University, </institution></institution-wrap>Maastricht, The Netherlands </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02jz4aj89</institution-id><institution-id institution-id-type="GRID">grid.5012.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 0481 6099</institution-id><institution>Institute of Nutrition and Translational Research in Metabolism (NUTRIM), </institution><institution>Maastricht University, </institution></institution-wrap>Maastricht, The Netherlands </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02jz4aj89</institution-id><institution-id institution-id-type="GRID">grid.5012.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 0481 6099</institution-id><institution>Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, </institution></institution-wrap>Maastricht, The Netherlands </aff><aff id="Aff4"><label>4</label>Ans Punt Computational Toxicology, Arnhem, The Netherlands </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03v2e2v10</institution-id><institution-id institution-id-type="GRID">grid.435742.3</institution-id><institution-id institution-id-type="ISNI">0000 0001 0726 7822</institution-id><institution>Office for Risk Assessment and Research, </institution><institution>Netherlands Food and Consumer Product Safety Authority (NVWA), </institution></institution-wrap>Utrecht, The Netherlands </aff></contrib-group><pub-date pub-type="epub"><day>3</day><month>4</month><year>2025</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>99</volume><issue>5</issue><issue-id pub-id-type="pmc-issue-id">488764</issue-id><fpage>1999</fpage><lpage>2021</lpage><history><date date-type="received"><day>25</day><month>9</month><year>2024</year></date><date date-type="accepted"><day>13</day><month>2</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>03</day><month>04</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>19</day><month>05</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-05-19 09:25:23.523"><day>19</day><month>05</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="204_2025_Article_3992.pdf"/><abstract id="Abs1"><p id="Par1">The present study predicts effective doses of a set of phenethylamine (PEA) analogues that are frequently present in pre-workout and weight-loss food supplements, to prioritize these compounds for further risk assessment. In vitro determined EC<sub>50</sub> values of PEA analogues for multiple human adrenergic receptor (ADR) subtypes (ADR&#945;<sub>1A</sub>, &#945;<sub>1B</sub>, &#945;<sub>1D</sub>, &#945;<sub>2A</sub>, &#946;<sub>1</sub>, &#946;<sub>2</sub>) and trace-amine associated receptor 1 (TAAR1) were extrapolated to human ED<sub>50</sub> values by using physiologically based kinetic (PBK) modelling-based reverse dosimetry combined with in silico and in vitro determined PBK model input parameters. The predicted ED<sub>50</sub> values of the studied PEAs for activation of ADR&#945;<sub>1A/B/D</sub>, ADR&#945;<sub>2A</sub>, ADR&#946;<sub>1</sub> and TAAR1 were within a range of 0.914&#8211;29.7&#160;mg/kg body weight (bw), 139&#8211;234&#160;mg/kg bw, 0.0839&#8211;38.8&#160;mg/kg bw and 0.995&#8211;264&#160;mg/kg bw, respectively. Comparison of the predicted ED<sub>50</sub> values with reported intake values revealed that particularly the exposure of the PEA analogues higenamine, isopropyloctopamine, &#946;-methylphenethylamine and p-synephrine is in the same range or exceeds the predicted ED<sub>50</sub> values. This suggests that these PEAs can (in)directly affect the cardiovascular system after the intake of food supplements. These PEA analogues should therefore be considered as high priority compounds for further risk assessment. In conclusion, our study shows that the use of quantitative in vitro-to-in vivo extrapolation (QIVIVE) of adrenergic and TAAR1 potencies using a generic PBK model can serve as an efficient prioritization method for a whole set of chemical analogues.</p><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1007/s00204-025-03992-7.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>QIVIVE</kwd><kwd>Phenethylamine analogues</kwd><kwd>Adrenergic receptors</kwd><kwd>Trace amine-associated receptor 1</kwd><kwd>PBK modelling</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100013890</institution-id><institution>Ministerie van Landbouw, Natuur en Voedselkwaliteit</institution></institution-wrap></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer-Verlag GmbH Germany, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2">The use of food supplements containing pharmacologically active substances to enhance sports performance and weight loss is increasing (Razenberg et al. <xref ref-type="bibr" rid="CR57">2021</xref>; Wardenaar et al. <xref ref-type="bibr" rid="CR68">2014</xref>). Among these substances, phenethylamine (PEA) analogues comprise a large group of compounds that are frequently used in such supplements (Avula et al. <xref ref-type="bibr" rid="CR4">2019</xref>; Biesterbos et al. <xref ref-type="bibr" rid="CR6">2019</xref>). PEA is a biogenic amine that is structurally related to the stimulant amphetamine and to the endogenous catecholamines (nor)adrenaline and dopamine (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). The use of supplements containing PEA analogues has been associated with numerous adverse cardiovascular events, including palpitations, tachycardia, myocardial infarct and hemorrhagic stroke (Bovee et al. <xref ref-type="bibr" rid="CR7">2016</xref>; Cohen et al. <xref ref-type="bibr" rid="CR10">2015a</xref>; de Jonge et al. <xref ref-type="bibr" rid="CR14">2023</xref>; Harris et al. <xref ref-type="bibr" rid="CR25">2017</xref>; Smith et al. <xref ref-type="bibr" rid="CR61">2014</xref>). Surprisingly, there generally is a lack of knowledge regarding the toxicological mechanisms and effects of these substances upon exposure. Despite the scarcity of available information, supplements containing PEA analogues are widely available on the market, are still being used on a large scale and are even becoming more popular in the last few years (Razenberg et al. <xref ref-type="bibr" rid="CR57">2021</xref>; Wardenaar et al. <xref ref-type="bibr" rid="CR68">2014</xref>). This urges for better regulation of such supplements to protect consumers against their potential adverse health effects.<fig id="Fig1" position="float" orientation="portrait"><label>Fig.&#160;1</label><caption><p>Molecular structures of (a) well-known activators of the sympathetic nervous system and (b) phenethylamine and its analogues detected in food supplements</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="204_2025_3992_Fig1_HTML.jpg"/></fig></p><p id="Par3">The detrimental effects of the PEA analogues on the cardiovascular system are suggested to be the result of mimicking activation of the sympathetic nervous system via various mechanisms (Broadley <xref ref-type="bibr" rid="CR8">2010</xref>); (Pinckaers et al. <xref ref-type="bibr" rid="CR52">2024</xref>; Rickli et al. <xref ref-type="bibr" rid="CR58">2019</xref>). Previous research showed that many PEA analogues are able to activate one or multiple adrenergic receptors (ADRs) and/or the trace amine-associated receptor 1 (TAAR1) in vitro (Pinckaers et al. <xref ref-type="bibr" rid="CR52">2024</xref>). These receptors play a critical role in cardiovascular homeostasis by regulating vascular smooth muscle- and cardiac contraction (Graham <xref ref-type="bibr" rid="CR22">1990</xref>). However, it is hard to causally link the adverse health effects to exposure to these compounds, as in vivo effects and kinetic data for most of these compounds are lacking. Consequently, it is not possible to perform a thorough risk assessment of these PEA analogues.</p><p id="Par4">To stimulate proper regulation and risk communication of the use of these potentially hazardous substances in food supplements, there is a need for data on their safety profile. In the past, experimental animal studies would predominantly be performed to obtain toxicological data on chemical substances and used to predict their safety for humans. However, during the last decades, food and chemical risk assessment are more and more reducing the use of animal studies for ethical, economical and translatability reasons and replacing them with new techniques to assess chemical toxicity, also known as New Approach Methodologies (NAMs). NAMs include any in vitro, in silico or chemistry-based method that may be used to acquire information that could be valuable for chemical safety assessment for instance by predicting the&#160;point of departure for safe exposure levels in humans (Fischer et al. <xref ref-type="bibr" rid="CR19">2020</xref>).</p><p id="Par5">An example of such a NAM is a physiologically based kinetic (PBK) model: an in silico tool that predicts absorption, distribution, metabolism and excretion (ADME) (Louisse et al. <xref ref-type="bibr" rid="CR42">2017</xref>). PBK modelling-based reverse dosimetry enables the translation of in vitro effect concentrations to in vivo effects doses. This quantitative in vitro-to-in vivo extrapolation (QIVIVE) can serve as an approach to prioritize compounds for additional risk assessment and in this way accelerate human health safety assessment (Paul Friedman et al. <xref ref-type="bibr" rid="CR49">2019</xref>). Currently, there is a need for case studies to gain confidence in PBK model predictions on the way towards regulatory acceptance of these models (Najjar et al. <xref ref-type="bibr" rid="CR43">2022</xref>; Otto et al. <xref ref-type="bibr" rid="CR47">2023</xref>). In the present study, a set of PEA analogues, that are frequently present in pre-workout and weight loss food supplements (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>b), is selected as a case for the application of the QIVIVE of adrenergic and TAAR1 potencies. In vitro determined EC<sub>50</sub> values of PEA analogues for ADR&#945;<sub>1A</sub>, &#945;<sub>1B</sub>, &#945;<sub>1D</sub>, &#945;<sub>2A</sub>, &#946;<sub>1</sub>, &#946;<sub>2</sub> and TAAR1 are extrapolated to ED<sub>50</sub> values by using PBK modelling-based reverse dosimetry combined with in silico and in vitro determined PBK model input parameters.</p></sec><sec id="Sec2"><title>Materials and methods</title><sec id="Sec3"><title>Chemicals</title><p id="Par6">&#914;-methylphenethylamine (99%), phenethylamine (99.7%), tyramine hydrochloride (&#8805;&#8201;98%), halostachine (99%), hordenine (&#8805;&#8201;97.5%), octopamine (&#8805;&#8201;95%), uridine 5&#8217;-diphosphoglucuronic acid trisodium salt (UDPGA), alamethicin, adenosine 3&#8217;-phosphate 5&#8217;-phosphosulfate lithium salt hydrate (PAPS), S-(5&#8217;-Adenosyl)-L-methionine <italic toggle="yes">p</italic>-toluenesulfonate salt (SAM), HEPES and ammonium formate were purchased from Sigma-Aldrich (St. Louis, USA). Synephrine hydrochloride (99.6%) and higenamine hydrochloride (98.98%) were purchased from MedChemExpress (Monmouth Junction, USA). Methyltyramine (97%) was purchased from Apollo Scientific (Stockport, United Kingdom). Sodium bicarbonate, dipotassium phosphate, monopotassium phosphate, magnesium chloride hexahydrate and formic acid (98&#8211;100%) were purchased from Merck (Darmstadt, Germany). Methylsynephrine hydrochloride (99.8%) was purchased from Mikromol (Luckenwalde, Germany), isopropyloctopamine acetate (99.9%) from Honeywell Fluka (Seetze, Germany), isopropyloctopamine hydrochloride (98%) from Toronto Research Chemicals (Toronto, Canada), N,N-dimethylphenethylamine hydrochloride (&gt;&#8201;99%) from GLPBio (Montclair, USA), metoprolol tartrate from EDQM (Strasbourg, France), acetonitrile from Biosolve (Valkenswaard, The Netherlands) and dimethylsulfoxide (DMSO) from Carl Roth (Karlsruhe, Germany). Nicotinamide adenine dinucleotide phosphate tetrasodium salt (NADPH) was purchased from Roche Diagnostics (Mannheim, Germany).</p></sec><sec id="Sec4"><title>Caco-2 permeability assays</title><p id="Par7">To predict the human effective intestinal permeability (P<sub>eff</sub>) and the intestinal uptake rate constant (k<sub>a</sub>) of the phenethylamine analogues, Caco-2 permeability coefficients (P<sub>app</sub>) were determined. Caco-2 cells (ATCC, Manassas, VA, USA; passage 30&#8211;44) were cultured in DMEM (Gibco, New York, USA) containing 4.5&#160;g/L d-glucose, 4&#160;mM L-glutamine and supplemented with 10% FBS (Gibco, Grand Island, NY, USA), 1% minimal essential medium non-essential amino acids (Gibco, Paisley, UK), 100 units/mL penicillin and 100&#160;&#181;g/mL streptomycin (Gibco, Grand Island, NY, USA). Cells were seeded at a density of 4.0&#8201;&#215;&#8201;10<sup>4</sup> cells/cm<sup>2</sup> on polyester transwell insert membranes (12&#160;mm insert, 0.4&#160;&#181;m pore size; Corning incorporated, Kennebunk, ME, USA). Cells were maintained in a humidified incubator with 5% CO<sub>2</sub> at 37&#160;&#176;C for 21 or 22&#160;days in 0.5&#160;mL and 1.5&#160;mL medium in the apical and basolateral compartments, respectively. The medium was refreshed every two or three days and always one day before the permeability assay.</p><p id="Par8">On the day of the experiment, cells were washed twice with HBSS without phenol red (pH 7.4; Sigma-Aldrich, Steinheim, Germany) supplemented with 0.35&#160;g/L sodium bicarbonate and 25&#160;mM HEPES and they were equilibrated in this supplemented HBSS for 15&#160;min in a humidified incubator with 5% CO<sub>2</sub> at 37&#160;&#176;C. Stocks of 10&#160;mM PEAs and metoprolol, which was used as a reference compound, were prepared in DMSO. These stocks were diluted to a final concentration of 10&#160;&#181;M in pre-warmed supplemented HBSS (final DMSO level&#8201;=&#8201;0.1%). After 15&#160;min, the transepithelial electrical resistance (TEER) was measured with an Epithelial Voltohmmeter (World Precision Instruments, Sarasota, USA). Compound transport was studied in two directions: from the apical to the basolateral compartment (A-B) and from the basolateral to the apical compartment (B-A). For A-B experiments, 450&#160;&#181;L of the compound (10&#160;&#181;M) was added to the apical side and 1200&#160;&#181;L supplemented HBSS was added to the basolateral side. A sample of 50&#160;&#181;L was removed immediately from the apical compartment at time point zero. After 15 and 30&#160;min, samples were taken from the basolateral compartment. Cells were kept in the incubator during the experiment. After 60&#160;min, medium from both compartments was sampled, cells were washed twice with supplemented HBSS and were maintained in the incubator. After 15&#160;min, the TEER was measured again to check for epithelial barrier damage due to compound exposure. After this, cells were lysed in RIPA buffer (Thermo Scientific, Rockford, IL, USA). For B-A experiments, 400&#160;&#181;L of supplemented HBSS was added to the apical side and 1250&#160;&#181;L of the compound (10&#160;&#181;M) was added to the basolateral side. A sample of 50&#160;&#181;L was removed immediately from the basolateral compartment at time point zero. After 15 and 30&#160;min, samples were taken from the apical compartment. After 60&#160;min, samples were taken similarly as in A-B experiments. The sampled medium and cell lysates were stored at &#8722;20&#160;&#176;C till the day of the liquid chromatography&#8211;mass spectrometry (LC&#8211;MS/MS) analysis. All experiments were run in duplicate. The compounds were quantified with LC&#8211;MS/MS as described in Sect.&#160;"<xref rid="Sec10" ref-type="sec">LC&#8211;MS/MS analysis</xref>".</p><p id="Par9">Before chemical analysis, cell lysates were two times diluted in ice-cold methanol and centrifuged at 15,000&#160;rpm at 4&#160;&#176;C. The supernatant was then injected into the LC&#8211;MS/MS system. Sampled buffer from donor compartments was diluted 40 times in buffer and samples from the receiver compartment were analysed undiluted. Standards were prepared in the same assay buffer to quantify the amount of compound in medium samples. For quantification of compounds in cell lysates, standards were prepared in a mixture of 50% RIPA buffer and 50% methanol.</p><p id="Par10">The effective intestinal permeability (P<sub>app</sub>) values were calculated according to the methods of Hubatsch et al. (<xref ref-type="bibr" rid="CR29">2007</xref>):<disp-formula id="Equa"><alternatives><tex-math id="d33e403">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\text{P}}_{{{\text{app}}}} \left( {{\text{cm}}/{\text{s}}} \right) = \left( {{{{\text{dQ}}} \mathord{\left/ {\vphantom {{{\text{dQ}}} {{\text{dt}}}}} \right. \kern-0pt} {{\text{dt}}}}} \right)({1 \mathord{\left/ {\vphantom {1 {\left( {{\text{A}}*{\text{C}}_{0} } \right)}}} \right. \kern-0pt} {\left( {{\text{A}}*{\text{C}}_{0} } \right)}}$$\end{document}</tex-math><mml:math id="d33e408" display="block"><mml:mrow><mml:msub><mml:mtext>P</mml:mtext><mml:mtext>app</mml:mtext></mml:msub><mml:mfenced close=")" open="("><mml:mrow><mml:mtext>cm</mml:mtext><mml:mo stretchy="false">/</mml:mo><mml:mtext>s</mml:mtext></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mfenced close=")" open="("><mml:mrow><mml:mtext>dQ</mml:mtext><mml:mrow><mml:mo stretchy="true">/</mml:mo></mml:mrow><mml:mtext>dt</mml:mtext></mml:mrow></mml:mfenced><mml:mrow><mml:mo stretchy="false">(</mml:mo></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mrow><mml:mo stretchy="true">/</mml:mo></mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:mtext>A</mml:mtext><mml:mrow/><mml:mo>&#8727;</mml:mo><mml:msub><mml:mtext>C</mml:mtext><mml:mn>0</mml:mn></mml:msub></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="204_2025_3992_Article_Equa.gif"/></alternatives></disp-formula>where dQ/dt is the steady-state flux in &#181;mol/s, A is the surface area of the cell culture insert membrane in cm<sup>2</sup> and C<sub>0</sub> is the starting concentration in &#181;M in the donor compartment (apical compartment for A-B and basolateral compartment for B-A experiments). Efflux ratios were determined by P<sub>app B-A</sub> / P<sub>app A-B</sub>. Caco-2 permeability assays are known to have high interlaboratory variability, which could be caused by Caco-2 passage number, filter membrane material, cell density and for example medium or assay buffer (Lee et al. <xref ref-type="bibr" rid="CR38">2017</xref>). To make our results comparable with other (future) studies, a correction factor for this interlaboratory variation was applied. All P<sub>app A-B</sub> values used for the calculation of P<sub>eff</sub> and k<sub>a</sub> were corrected for the fold change of the P<sub>app A-B</sub> of metoprolol in the current study and the average of the P<sub>app A-B</sub> of metoprolol presented in the literature. As metoprolol is a widely studied compound, it is therefore chosen as a reference compound in the current study to correct for the aforementioned variables that may influence compound permeability. All data are presented as mean&#8201;&#177;&#8201;SD.</p></sec><sec id="Sec5"><title>In vitro hepatic clearance by human liver S9</title><p id="Par11">In vitro intrinsic hepatic clearance (CL<sub>int</sub>) values of the phenethylamine analogues were determined in experiments with pooled human liver S9 (HLS9; Corning, Woburn, MA, USA and Gibco, USA), by measuring the rate of compound depletion. Stocks of 1&#160;mM PEA compounds were prepared in DMSO and stocks of 10&#160;mg/mL alamethicin were prepared in methanol. The final incubation mixtures consisted of 1&#160;&#181;M of PEA compound (0.1% DMSO) in 100&#160;mM potassium phosphate buffer with 5&#160;mM magnesium chloride (pH 7.4) supplemented with 0.025&#160;mg/mL alamethicin (0.25% methanol) and 0.1&#8211;2&#160;mg/mL HLS9. Optimal HLS9 concentrations for each compound were determined in separate pilot experiments by testing multiple HLS9 concentrations; the HLS9 concentration that showed a linear substrate depletion between 0 and 60&#160;min was chosen. The optimal HLS9 concentrations are presented in Table&#160;<xref rid="Tab1" ref-type="table">1</xref>. Incubation mixtures were first pre-incubated at 37&#160;&#176;C in a shaking incubator at 300&#160;rpm for 5&#160;min. After 5&#160;min, the reaction was initiated by adding a co-factor mix in supplemented buffer with final concentrations of 3&#160;mM nicotinamide adenine dinucleotide phosphate (NADPH; for oxidation, reduction and hydrolysis), 5&#160;mM uridine diphosphate glucuronic acid (UDPGA; for glucuronidation), 0.2&#160;mM adenosine 3&#8217;-phosphate 5&#8217;-phosphosulfate lithium salt hydrate (PAPS; for sulfation) and 0.2&#160;mM S-(5&#8217;-Adenosyl)-L-methionine p-toluenesulfonate salt (SAM; for methylation). The final incubation volume was 100&#160;&#181;L and incubations were performed in 1.5&#160;mL Safe-Lock Eppendorf tubes (Eppendorf) in a shaking incubator (300&#160;rpm) at 37&#160;&#176;C (Eppendorf Thermomixer). Incubations were terminated by adding 100 &#181;L ice-cold acetonitrile after, 0, 2.5, 5, 10, 20, 40 and 60&#160;min. Then, samples were vortexed, put on ice and stored at -20&#160;&#176;C until the day of the LC&#8211;MS/MS analysis. Controls of incubation mixtures without HLS9 or mixtures without co-factors were also included. Two independent experiments, both in duplicate, were performed on different days. On the day of the LC&#8211;MS/MS analysis, samples were thawed and centrifuged at 15,000&#160;rpm for 10&#160;min. The supernatant was collected in glass insert vials for LC injection (BGB Analytik, Harderwijk, The Netherlands). Details on the methods of the LC&#8211;MS/MS analysis are described in Sect.&#160;"<xref rid="Sec10" ref-type="sec">LC&#8211;MS/MS analysis</xref>". After determining the PEA (analogue) amount at the different time points, the CL<sub>int</sub> was calculated. The natural logarithm of compound concentrations was plotted against time and the slope of this curve represented the elimination rate constant k (in 1/min). The half-life (t<sub>1/2</sub> in minutes) was calculated by: ln (2)/k (in 1/min). The volume of incubation (V) in &#181;L/mg protein was determined by: 1000 / HLS9 concentration (in mg/mL). Finally, CL<sub>int</sub> could be calculated by:<disp-formula id="Equb"><alternatives><tex-math id="d33e487">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\text{CL}}_{{{\text{int}}}} \left( {\mu {\text{L}}/{\text{min}}/{\text{mg protein}}} \right) = {\text{V}}\left( {\mu {\text{L}}/{\text{mg protein}}} \right)*\left( {{\text{ln }}\left( {2} \right)/{\text{t}}_{{{1}/{2}}} \left( {{\text{min}}} \right)} \right).$$\end{document}</tex-math><mml:math id="d33e492" display="block"><mml:mrow><mml:msub><mml:mtext>CL</mml:mtext><mml:mtext>int</mml:mtext></mml:msub><mml:mfenced close=")" open="("><mml:mrow><mml:mi>&#956;</mml:mi><mml:mtext>L</mml:mtext><mml:mo stretchy="false">/</mml:mo><mml:mtext>min</mml:mtext><mml:mo stretchy="false">/</mml:mo><mml:mrow><mml:mtext>mg protein</mml:mtext></mml:mrow></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mtext>V</mml:mtext><mml:mfenced close=")" open="("><mml:mrow><mml:mi>&#956;</mml:mi><mml:mtext>L</mml:mtext><mml:mo stretchy="false">/</mml:mo><mml:mrow><mml:mtext>mg protein</mml:mtext></mml:mrow></mml:mrow></mml:mfenced><mml:mrow/><mml:mo>&#8727;</mml:mo><mml:mfenced close=")" open="("><mml:mrow><mml:mrow><mml:mtext>ln</mml:mtext><mml:mspace width="0.333333em"/></mml:mrow><mml:mfenced close=")" open="("><mml:mn>2</mml:mn></mml:mfenced><mml:mo stretchy="false">/</mml:mo><mml:msub><mml:mtext>t</mml:mtext><mml:mrow><mml:mn>1</mml:mn><mml:mo stretchy="false">/</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mfenced close=")" open="("><mml:mtext>min</mml:mtext></mml:mfenced></mml:mrow></mml:mfenced><mml:mo>.</mml:mo></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="204_2025_3992_Article_Equb.gif"/></alternatives></disp-formula><table-wrap id="Tab1" position="float" orientation="portrait"><label>Table&#160;1</label><caption><p>Human liver S9 concentrations used in the incubations with the specific phenethylamine analogues</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Compound</th><th align="left" colspan="1" rowspan="1">Human liver S9 concentration (mg/mL)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">&#946;-Methylphenethylamine</td><td align="left" colspan="1" rowspan="1">2</td></tr><tr><td align="left" colspan="1" rowspan="1">Dimethylphenethylamine</td><td align="left" colspan="1" rowspan="1">2</td></tr><tr><td align="left" colspan="1" rowspan="1">Halostachine</td><td align="left" colspan="1" rowspan="1">0.5</td></tr><tr><td align="left" colspan="1" rowspan="1">Higenamine</td><td align="left" colspan="1" rowspan="1">1</td></tr><tr><td align="left" colspan="1" rowspan="1">Hordenine</td><td align="left" colspan="1" rowspan="1">2</td></tr><tr><td align="left" colspan="1" rowspan="1">Isopropyloctopamine</td><td align="left" colspan="1" rowspan="1">2</td></tr><tr><td align="left" colspan="1" rowspan="1">Methylsynephrine</td><td align="left" colspan="1" rowspan="1">2</td></tr><tr><td align="left" colspan="1" rowspan="1">Methyltyramine</td><td align="left" colspan="1" rowspan="1">0.25</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic>-Octopamine</td><td align="left" colspan="1" rowspan="1">2</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic>-Synephrine</td><td align="left" colspan="1" rowspan="1">1</td></tr><tr><td align="left" colspan="1" rowspan="1">Phenethylamine</td><td align="left" colspan="1" rowspan="1">0.1</td></tr><tr><td align="left" colspan="1" rowspan="1">Tyramine</td><td align="left" colspan="1" rowspan="1">0.25</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec6"><title>In silico predicted input parameters</title><p id="Par12">Physicochemical input data, such as pKa, logP and molecular weight (MW) were obtained from Chemicalize (April 2023, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://chemicalize.com/">https://chemicalize.com/</ext-link>, developed by ChemAxon). Blood:plasma (B:P) ratios were predicted with the Simcyp ADME Prediction Toolbox V1.1 (Simcyp Limited 2012). The fraction unbound in plasma (F<sub>up</sub>) was predicted according to the method of (Lobell and Sivarajah <xref ref-type="bibr" rid="CR41">2003</xref>) and obtained via the QIVIVE toolbox from (Punt et al. <xref ref-type="bibr" rid="CR54">2021b</xref>) <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.qivivetools.wur.nl">http://www.qivivetools.wur.nl</ext-link>). Tissue:plasma partition coefficients were simulated by the method of (Rodgers and Rowland <xref ref-type="bibr" rid="CR59">2006</xref>) and obtained via the QIVIVE toolbox (Punt et al. <xref ref-type="bibr" rid="CR54">2021b</xref>). The physicochemical properties of the PEAs that were used to predict tissue:plasma partition coefficients are presented in Table&#160;<xref rid="Tab2" ref-type="table">2</xref>.<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table&#160;2</label><caption><p>Physicochemical properties of the phenethylamines used to calculate tissue:plasma partition coefficients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Compound</th><th align="left" colspan="1" rowspan="1">pKa<sup>a</sup></th><th align="left" colspan="1" rowspan="1">logP</th><th align="left" colspan="1" rowspan="1">MW</th><th align="left" colspan="1" rowspan="1">Fraction unbound (F<sub>up</sub>)</th><th align="left" colspan="1" rowspan="1">Blood:plasma ratio</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">&#946;-Methylphenethylamine</td><td char="." align="char" colspan="1" rowspan="1">9.66</td><td char="." align="char" colspan="1" rowspan="1">1.753</td><td char="." align="char" colspan="1" rowspan="1">135.21</td><td char="." align="char" colspan="1" rowspan="1">0.657</td><td char="." align="char" colspan="1" rowspan="1">1.1638</td></tr><tr><td align="left" colspan="1" rowspan="1">Dimethylphenethylamine</td><td char="." align="char" colspan="1" rowspan="1">9.41</td><td char="." align="char" colspan="1" rowspan="1">2.203</td><td char="." align="char" colspan="1" rowspan="1">149.237</td><td char="." align="char" colspan="1" rowspan="1">0.541</td><td char="." align="char" colspan="1" rowspan="1">1.1945</td></tr><tr><td align="left" colspan="1" rowspan="1">Halostachine</td><td char="." align="char" colspan="1" rowspan="1">9.43</td><td char="." align="char" colspan="1" rowspan="1">0.901</td><td char="." align="char" colspan="1" rowspan="1">151.209</td><td char="." align="char" colspan="1" rowspan="1">0.825</td><td char="." align="char" colspan="1" rowspan="1">1.0416</td></tr><tr><td align="left" colspan="1" rowspan="1">Higenamine</td><td char="." align="char" colspan="1" rowspan="1">8.57</td><td char="." align="char" colspan="1" rowspan="1">2.35</td><td char="." align="char" colspan="1" rowspan="1">271.316</td><td char="." align="char" colspan="1" rowspan="1">0.484</td><td char="." align="char" colspan="1" rowspan="1">1.2151</td></tr><tr><td align="left" colspan="1" rowspan="1">Hordenine</td><td char="." align="char" colspan="1" rowspan="1">8.88</td><td char="." align="char" colspan="1" rowspan="1">1.563</td><td char="." align="char" colspan="1" rowspan="1">165.236</td><td char="." align="char" colspan="1" rowspan="1">0.694</td><td char="." align="char" colspan="1" rowspan="1">1.1442</td></tr><tr><td align="left" colspan="1" rowspan="1">Isopropyloctopamine</td><td char="." align="char" colspan="1" rowspan="1">9.84</td><td char="." align="char" colspan="1" rowspan="1">0.629</td><td char="." align="char" colspan="1" rowspan="1">195.262</td><td char="." align="char" colspan="1" rowspan="1">0.864</td><td char="." align="char" colspan="1" rowspan="1">0.996</td></tr><tr><td align="left" colspan="1" rowspan="1">Methylsynephrine</td><td char="." align="char" colspan="1" rowspan="1">9.8</td><td char="." align="char" colspan="1" rowspan="1">0.284</td><td char="." align="char" colspan="1" rowspan="1">181.235</td><td char="." align="char" colspan="1" rowspan="1">0.902</td><td char="." align="char" colspan="1" rowspan="1">0.9383</td></tr><tr><td align="left" colspan="1" rowspan="1">Methyltyramine</td><td char="." align="char" colspan="1" rowspan="1">10.39</td><td char="." align="char" colspan="1" rowspan="1">0.804</td><td char="." align="char" colspan="1" rowspan="1">151.209</td><td char="." align="char" colspan="1" rowspan="1">0.841</td><td char="." align="char" colspan="1" rowspan="1">1.026</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic>-Octopamine</td><td char="." align="char" colspan="1" rowspan="1">8.64</td><td char="." align="char" colspan="1" rowspan="1">&#8722;0.131</td><td char="." align="char" colspan="1" rowspan="1">153.181</td><td char="." align="char" colspan="1" rowspan="1">0.93</td><td char="." align="char" colspan="1" rowspan="1">0.8657</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic>-Synephrine</td><td char="." align="char" colspan="1" rowspan="1">9.15</td><td char="." align="char" colspan="1" rowspan="1">&#8722;0.071</td><td char="." align="char" colspan="1" rowspan="1">167.208</td><td char="." align="char" colspan="1" rowspan="1">0.929</td><td char="." align="char" colspan="1" rowspan="1">0.8802</td></tr><tr><td align="left" colspan="1" rowspan="1">Phenethylamine</td><td char="." align="char" colspan="1" rowspan="1">9.94</td><td char="." align="char" colspan="1" rowspan="1">1.388</td><td char="." align="char" colspan="1" rowspan="1">121.183</td><td char="." align="char" colspan="1" rowspan="1">0.739</td><td char="." align="char" colspan="1" rowspan="1">1.1187</td></tr><tr><td align="left" colspan="1" rowspan="1">Tyramine</td><td char="." align="char" colspan="1" rowspan="1">9.34</td><td char="." align="char" colspan="1" rowspan="1">0.605</td><td char="." align="char" colspan="1" rowspan="1">137.182</td><td char="." align="char" colspan="1" rowspan="1">0.866</td><td char="." align="char" colspan="1" rowspan="1">0.991</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>All compounds are monoprotic bases</p></table-wrap-foot></table-wrap></p><p id="Par13">The in vitro obtained Caco-2 P<sub>app</sub> values were scaled to in vivo absorption rate constants (k<sub>a</sub>) and fraction absorbed (fa) with the following equations:<disp-formula id="Equ1"><label>1</label><alternatives><tex-math id="d33e857">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\text{log P}}_{{{\text{eff}}}} ,{\text{human}}\left( {{1}0^{{ - {4}}} {\text{cm}}/{\text{s}}} \right) = 0.{4926}*{\text{log P}}_{{{\text{app}}}} \left( {{1}0^{{ - {6}}} {\text{cm}}/{\text{s}}} \right){-}0.{1454}$$\end{document}</tex-math><mml:math id="d33e863" display="block"><mml:mrow><mml:msub><mml:mrow><mml:mtext>log P</mml:mtext></mml:mrow><mml:mtext>eff</mml:mtext></mml:msub><mml:mo>,</mml:mo><mml:mtext>human</mml:mtext><mml:mfenced close=")" open="("><mml:mrow><mml:mn>1</mml:mn><mml:msup><mml:mn>0</mml:mn><mml:mrow><mml:mo>-</mml:mo><mml:mn>4</mml:mn></mml:mrow></mml:msup><mml:mtext>cm</mml:mtext><mml:mo stretchy="false">/</mml:mo><mml:mtext>s</mml:mtext></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mn>0.4926</mml:mn><mml:mrow/><mml:mo>&#8727;</mml:mo><mml:msub><mml:mrow><mml:mtext>log P</mml:mtext></mml:mrow><mml:mtext>app</mml:mtext></mml:msub><mml:mfenced close=")" open="("><mml:mrow><mml:mn>1</mml:mn><mml:msup><mml:mn>0</mml:mn><mml:mrow><mml:mo>-</mml:mo><mml:mn>6</mml:mn></mml:mrow></mml:msup><mml:mtext>cm</mml:mtext><mml:mo stretchy="false">/</mml:mo><mml:mtext>s</mml:mtext></mml:mrow></mml:mfenced><mml:mo>-</mml:mo><mml:mn>0.1454</mml:mn></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="204_2025_3992_Article_Equ1.gif"/></alternatives></disp-formula><disp-formula id="Equ2"><label>2</label><alternatives><tex-math id="d33e907">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\text{k}}_{{\text{a}}} \left( {/{\text{h}}} \right) = {\text{P}}_{{{\text{eff}}}} *{2}\left( {{\text{cm}}/{\text{s}}} \right)/{\text{R}}\left( {{\text{cm}}} \right)*{36}00\left( {{\text{s}}/{\text{h}}} \right)$$\end{document}</tex-math><mml:math id="d33e913" display="block"><mml:mrow><mml:msub><mml:mtext>k</mml:mtext><mml:mtext>a</mml:mtext></mml:msub><mml:mfenced close=")" open="("><mml:mrow><mml:mo stretchy="false">/</mml:mo><mml:mtext>h</mml:mtext></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:msub><mml:mtext>P</mml:mtext><mml:mtext>eff</mml:mtext></mml:msub><mml:mrow/><mml:mo>&#8727;</mml:mo><mml:mn>2</mml:mn><mml:mfenced close=")" open="("><mml:mrow><mml:mtext>cm</mml:mtext><mml:mo stretchy="false">/</mml:mo><mml:mtext>s</mml:mtext></mml:mrow></mml:mfenced><mml:mo stretchy="false">/</mml:mo><mml:mtext>R</mml:mtext><mml:mfenced close=")" open="("><mml:mtext>cm</mml:mtext></mml:mfenced><mml:mrow/><mml:mo>&#8727;</mml:mo><mml:mn>3600</mml:mn><mml:mfenced close=")" open="("><mml:mrow><mml:mtext>s</mml:mtext><mml:mo stretchy="false">/</mml:mo><mml:mtext>h</mml:mtext></mml:mrow></mml:mfenced></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="204_2025_3992_Article_Equ2.gif"/></alternatives></disp-formula><disp-formula id="Equ3"><label>3</label><alternatives><tex-math id="d33e952">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\text{fa}} = {1}{-}({1} + \left( {{2}*{\text{P}}_{{{\text{eff}}}} * &lt; {\text{Tsi}}&gt; } \right)/\left( {{7}*{\text{R}}} \right)^{{ - {7}}}$$\end{document}</tex-math><mml:math id="d33e958" display="block"><mml:mrow><mml:mtext>fa</mml:mtext><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfenced close=")" open="("><mml:mrow><mml:mn>2</mml:mn><mml:mrow/><mml:mo>&#8727;</mml:mo><mml:msub><mml:mtext>P</mml:mtext><mml:mtext>eff</mml:mtext></mml:msub><mml:mrow/><mml:mo>&#8727;</mml:mo><mml:mo>&lt;</mml:mo><mml:mtext>Tsi</mml:mtext><mml:mo>&gt;</mml:mo></mml:mrow></mml:mfenced><mml:mo stretchy="false">/</mml:mo><mml:msup><mml:mfenced close=")" open="("><mml:mrow><mml:mn>7</mml:mn><mml:mrow/><mml:mo>&#8727;</mml:mo><mml:mtext>R</mml:mtext></mml:mrow></mml:mfenced><mml:mrow><mml:mo>-</mml:mo><mml:mn>7</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="204_2025_3992_Article_Equ3.gif"/></alternatives></disp-formula>in which P<sub>eff</sub> is the effective permeability in humans, R is the intestinal radius and&#8201;&lt;&#8201;Tsi&#8201;&gt;&#8201;is the transit time in the small intestine. Equation&#160;(<xref rid="Equ1" ref-type="disp-formula">1</xref>) is based on the human study of (Sun et al. <xref ref-type="bibr" rid="CR62">2002</xref>), in which in vivo intestinal effective permeability is correlated to in vitro Caco-2 P<sub>app</sub> values. Equations&#160;(<xref rid="Equ2" ref-type="disp-formula">2</xref>) and (<xref rid="Equ3" ref-type="disp-formula">3</xref>) are based on the methods of (Yu and Amidon <xref ref-type="bibr" rid="CR71">1999</xref>), in which R is 1&#160;cm and is obtained from (Peters and Hultin <xref ref-type="bibr" rid="CR51">2008</xref>). For the&#8201;&lt;&#8201;Tsi&#8201;&gt;&#8201;a value of 3.32&#160;h was used (Grandoni et al. <xref ref-type="bibr" rid="CR23">2019</xref>).</p><p id="Par14">The fraction unbound in these in vitro liver clearance incubations was calculated with the method of (Hallifax and Houston <xref ref-type="bibr" rid="CR24">2006</xref>) in which unspecific binding in HLS9 incubations was assumed to be the same as in liver microsomal incubations. The in vitro obtained HLS9 CL<sub>int</sub> values were corrected for protein binding in the HLS9 incubation and were scaled to a whole liver by using a scaling factor of 121&#160;mg HLS9/g liver (Houston and Galetin <xref ref-type="bibr" rid="CR28">2008</xref>).</p></sec><sec id="Sec7"><title>PBK model code and software</title><p id="Par15">The PBK model codes used in this study are presented in the Supplementary data. For the prediction of internal concentrations of the PEA analogues a generic PBK model for humans with oral dosing was used. The PBK model code was adopted from (Jones and Rowland-Yeo <xref ref-type="bibr" rid="CR34">2013</xref>). In general, the body compartments described in the model are: adipose, bone, brain, gut, heart, kidney, liver, lung, muscle, skin, spleen, testes, venous, arterial, plasma and a rest compartment. The concentrations in these compartments were modelled as blood-flow limited, in which it is assumed that the total concentration in the tissue is in equilibrium with the concentration in the systemic circulation at a steady state. The concentration in the circulation is compound-specific and is based on the plasma partition coefficients. The blood flow rate, the tissue volume and the plasma partition coefficients determine the rate of reaching the steady-state (Jones and Rowland-Yeo <xref ref-type="bibr" rid="CR34">2013</xref>). The model was converted to RStudio (version 2023.12.1 Build 402, &#8220;Ocean Storm Release&#8221;) solving the differential equations with the R rxode2 package (with tidyverse packages). C<sub>liver free</sub> was defined as C<sub>liver</sub>/K<sub>p liver</sub> * F<sub>up</sub> instead of C<sub>liver</sub>* F<sub>up</sub>. In addition, the fraction absorbed (fa) accounted for the initial setting of the dose rather than the differential equation for oral absorption, as the latter would present the absorption rate and not the fraction that is absorbed. The renal clearance (urinary excretion) was simulated as glomerular filtration rate (GFR) times the free plasma concentration. This is an adjustment from the original model by Jones and Rowland-Yeo (<xref ref-type="bibr" rid="CR34">2013</xref>), where renal clearance is described as CL<sub>renal</sub>*C<sub>kidney free</sub> and it is not specified whether this renal clearance corresponds to urinary excretion or metabolic clearance. Furthermore, the plasma concentration was, in this study, converted to &#181;mol/L or nmol/L as output of the model. The tissue partition coefficient of the testes and the remaining body compartment (K<sub>p re</sub>) was set equal to the muscle partition coefficient. Also, mass balance equations were added and V<sub>rb</sub>, V<sub>plas_ven</sub> and V<sub>plas_art</sub> were removed from the current model since these were not used in the current study.</p><p id="Par16">The above-described generic PBK model was converted to a model with intravenous dosing. Intravenous administration was included in this study, as the in vivo available data of higenamine, which was used for the PBK model evaluation, was administered intravenously. The dosing regimen of the intravenous PBK model corresponds to the dosing regimen used in the study of (Feng et al. <xref ref-type="bibr" rid="CR18">2012</xref>), which was an escalating infusion of 0.5, 1, 2 and 4&#160;&#181;g/kg bw/min. The infusion duration of each dose was three minutes, resulting in a total dose of 22.5&#160;&#181;g/kg bw after 12&#160;min of infusion.</p></sec><sec id="Sec8"><title>Sensitivity analysis</title><p id="Par17">The influence of the PBK model input parameters on the modelled venous plasma concentration (C<sub>plasma venous</sub>) was investigated by performing a local sensitivity analysis. Normalised sensitivity coefficients (NSC) were calculated according to:<disp-formula id="Equc"><alternatives><tex-math id="d33e1082">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\text{NSC}} = \left( {{\text{C}}^{\prime } - {\text{C}}} \right)/\left( {{\text{P}} - {\text{P}}^{\prime } } \right)*\left( {{\text{P}}/{\text{C}}} \right)$$\end{document}</tex-math><mml:math id="d33e1087" display="block"><mml:mrow><mml:mtext>NSC</mml:mtext><mml:mo>=</mml:mo><mml:mfenced close=")" open="("><mml:mrow><mml:msup><mml:mrow><mml:mtext>C</mml:mtext></mml:mrow><mml:mo>&#8242;</mml:mo></mml:msup><mml:mo>-</mml:mo><mml:mtext>C</mml:mtext></mml:mrow></mml:mfenced><mml:mo stretchy="false">/</mml:mo><mml:mfenced close=")" open="("><mml:mrow><mml:mtext>P</mml:mtext><mml:mo>-</mml:mo><mml:msup><mml:mrow><mml:mtext>P</mml:mtext></mml:mrow><mml:mo>&#8242;</mml:mo></mml:msup></mml:mrow></mml:mfenced><mml:mrow/><mml:mo>&#8727;</mml:mo><mml:mfenced close=")" open="("><mml:mrow><mml:mtext>P</mml:mtext><mml:mo stretchy="false">/</mml:mo><mml:mtext>C</mml:mtext></mml:mrow></mml:mfenced></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="204_2025_3992_Article_Equc.gif"/></alternatives></disp-formula>in which C is the model output (i.e. C<sub>plasma venous</sub>) and P is the input parameter (Evans and Andersen <xref ref-type="bibr" rid="CR16">2000</xref>). P&#8217; represents a 1% change of P and C&#8217; represents the value of C when applying P&#8217;.</p></sec><sec id="Sec9"><title>Prediction of oral equivalent effect doses</title><p id="Par18">The in vitro effect concentrations (EC<sub>50</sub>), for activation of the &#945;<sub>1A,</sub> &#945;<sub>1B,</sub> &#945;<sub>1D,</sub> &#945;<sub>2A,</sub> &#945;<sub>2B,</sub> &#946;<sub>1</sub> and &#946;<sub>2</sub> ADR activation and the activation of TAAR1, were obtained from our previous study (Pinckaers et al. <xref ref-type="bibr" rid="CR52">2024</xref>). These EC<sub>50</sub> values were extrapolated to ED<sub>50</sub> values in the current study as follow:<disp-formula id="Equd"><alternatives><tex-math id="d33e1153">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\text{predicted ED}}_{{{5}0}} = in \, vitro{\text{EC}}_{{{5}0}} *{\text{ 1 mg}}/{\text{kg bw }}/{\text{ modelled C}}_{{\text{max plasma venous}}} {\text{at 1 mg}}/{\text{kg bw}}_{.}$$\end{document}</tex-math><mml:math id="d33e1158" display="block"><mml:mrow><mml:msub><mml:mrow><mml:mtext>predicted ED</mml:mtext></mml:mrow><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mspace width="0.166667em"/><mml:mi>v</mml:mi><mml:mi>i</mml:mi><mml:mi>t</mml:mi><mml:mi>r</mml:mi><mml:mi>o</mml:mi><mml:msub><mml:mtext>EC</mml:mtext><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub><mml:mrow/><mml:mo>&#8727;</mml:mo><mml:mrow><mml:mspace width="0.333333em"/><mml:mtext>1 mg</mml:mtext></mml:mrow><mml:mo stretchy="false">/</mml:mo><mml:mrow><mml:mtext>kg bw</mml:mtext><mml:mspace width="0.333333em"/></mml:mrow><mml:mo stretchy="false">/</mml:mo><mml:msub><mml:mrow><mml:mspace width="0.333333em"/><mml:mtext>modelled C</mml:mtext></mml:mrow><mml:mrow><mml:mtext>max plasma venous</mml:mtext></mml:mrow></mml:msub><mml:mrow><mml:mtext>at 1 mg</mml:mtext></mml:mrow><mml:mo stretchy="false">/</mml:mo><mml:msub><mml:mrow><mml:mtext>kg bw</mml:mtext></mml:mrow><mml:mo>.</mml:mo></mml:msub></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="204_2025_3992_Article_Equd.gif"/></alternatives></disp-formula></p><p id="Par19">For this extrapolation, it was assumed that effects were only caused by the parent compound and not by its metabolites, and can be related to the peak plasma concentration.</p></sec><sec id="Sec10"><title>LC&#8211;MS/MS analysis</title><p id="Par20">Samples from the Caco-2 permeability assays and the in vitro hepatic clearance assays were analysed with an ultra-high-performance liquid chromotograph (UPLC) (Agilent Technologies, Santa Clara, CA, USA) coupled to an Agilent 6550 iFunnel quadrupole-time-of-flight (Q-TOF) mass spectrometer equipped with a dual electrospray ionization (ESI) source in positive mode with Agilent Jet Stream technology. The injection volume was 5&#160;&#181;L for &#946;-methylphenethylamine, isopropyloctopamine and metoprolol and was 2&#160;&#181;L for the remaining compounds. To measure &#946;-methylphenethylamine, dimethylphenethylamine, phenethylamine, methyltyramine, higenamine, hordenine, methylsynephrine, isopropyloctopamine and metoprolol, the UPLC system was equipped with an Agilent Technologies InfinityLab Poroshell 120 EC-C18 column (2.1&#8201;&#215;&#8201;100&#160;mm, 2.7&#160;&#181;m pore size) with a similar guard column (2.1&#8201;&#215;&#8201;5&#160;mm, 2.7&#160;&#181;m pore size). Halostachine, <italic toggle="yes">p</italic>-octopamine, <italic toggle="yes">p</italic>-synephrine and tyramine were separated by an InfinityLab Poroshell 120 HILIC column (2.1&#8201;&#215;&#8201;100&#160;mm, 2.7&#160;&#181;m pore size) equipped with a similar guard column (2.1&#8201;&#215;&#8201;5&#160;mm, 2.7&#160;&#181;m pore size). The temperature of the C18 column wash held at 25&#160;&#176;C and of the HILIC column at 30&#160;&#176;C. The temperature of the autosampler was kept at 4&#160;&#176;C. For compounds that eluted from the C18 column, a gradient of 0.1% formic acid in water (A) and acetonitrile (B) was used. The gradient started at 5% B, was kept at 5% B for 1&#160;min, and then linearly increased to 50% B in 10&#160;min. After 2&#160;min 50% B, the gradient linearly decreased to 5% B in 1&#160;min and was kept at 5% B for another 4&#160;min. For the compounds that eluted from the HILIC column, mobile phase A was 0.1% formic acid and 5&#160;mM ammonium formate in water and mobile phase B was acetonitrile. The gradient started at 92% B, was kept at 92% B for 9&#160;min, and then linearly decreased to 70% B in 0.5&#160;min and kept at 70% B for 3&#160;min. Then, the gradient linearly increased to 92% in 0.5&#160;min and was kept at 92% B for 4&#160;min.</p><p id="Par21">A sheat gas temperature of 350&#160;&#176;C, a sheat gas flow of 660&#160;L/h, a cone gas temperature of 200&#160;&#176;C and a cone gas flow of 840&#160;L/h was used. The nebulizer pressure was set at 35 psi. The capillary voltage, the nozzle voltage and the fragmentor voltage were 3500, 1000 and 380, respectively. Nitrogen was used as a collision-induced dissociation gas. Collision energy was optimized for each compound. Retention time, collision energy and mass charge (m/z) transitions for each compound are described in Table&#160;<xref rid="Tab3" ref-type="table">3</xref>. All ions were measured in positive ion mode (ESI&#8201;+). Data acquisition was performed using Agilent MassHunter Workstation Quantitative Analysis for Q-TOF software version 10.2 (Agilent Technologies, Inc.).<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table&#160;3</label><caption><p>Compound-specific mass spectrometry parameters</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Compound</th><th align="left" colspan="1" rowspan="1">Parent ion (m/z)</th><th align="left" colspan="1" rowspan="1">Daughter ion (m/z)<break/>(*&#8201;=&#8201;quantifier)</th><th align="left" colspan="1" rowspan="1">Collision energy<break/>(eV)</th><th align="left" colspan="1" rowspan="1">Retention time<break/>(minutes)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">&#946;-Methylphenethylamine</td><td align="left" colspan="1" rowspan="1">136.11</td><td align="left" colspan="1" rowspan="1">91.05 *</td><td align="left" colspan="1" rowspan="1">12.5</td><td char="." align="char" colspan="1" rowspan="1">5.2</td></tr><tr><td align="left" colspan="1" rowspan="1">Dimethylphenethylamine</td><td align="left" colspan="1" rowspan="1">150.13</td><td align="left" colspan="1" rowspan="1">105.07 *</td><td align="left" colspan="1" rowspan="1">20</td><td char="." align="char" colspan="1" rowspan="1">4.8</td></tr><tr><td align="left" colspan="1" rowspan="1">Halostachine</td><td align="left" colspan="1" rowspan="1">134.10 / 152.11</td><td align="left" colspan="1" rowspan="1">119.10 / 134.10 *</td><td align="left" colspan="1" rowspan="1">22.5 / 10</td><td char="." align="char" colspan="1" rowspan="1">2.6</td></tr><tr><td align="left" colspan="1" rowspan="1">Higenamine</td><td align="left" colspan="1" rowspan="1">272.13</td><td align="left" colspan="1" rowspan="1">107.050 *</td><td align="left" colspan="1" rowspan="1">30</td><td char="." align="char" colspan="1" rowspan="1">5.1</td></tr><tr><td align="left" colspan="1" rowspan="1">Hordenine</td><td align="left" colspan="1" rowspan="1">166.12</td><td align="left" colspan="1" rowspan="1">121.06 *</td><td align="left" colspan="1" rowspan="1">30</td><td char="." align="char" colspan="1" rowspan="1">1.9</td></tr><tr><td align="left" colspan="1" rowspan="1">Isopropyloctopamine</td><td align="left" colspan="1" rowspan="1">178.12</td><td align="left" colspan="1" rowspan="1">91.05 *</td><td align="left" colspan="1" rowspan="1">30</td><td char="." align="char" colspan="1" rowspan="1">2.3</td></tr><tr><td align="left" colspan="1" rowspan="1">Methylsynephrine</td><td align="left" colspan="1" rowspan="1">182.12 / 164.11</td><td align="left" colspan="1" rowspan="1">164.11 * / 149.08</td><td align="left" colspan="1" rowspan="1">10 / 20</td><td char="." align="char" colspan="1" rowspan="1">1.4</td></tr><tr><td align="left" colspan="1" rowspan="1">Methyltyramine</td><td align="left" colspan="1" rowspan="1">152.1</td><td align="left" colspan="1" rowspan="1">121.06 *</td><td align="left" colspan="1" rowspan="1">8</td><td char="." align="char" colspan="1" rowspan="1">1.8</td></tr><tr><td align="left" colspan="1" rowspan="1">Metoprolol</td><td align="left" colspan="1" rowspan="1">268.20</td><td align="left" colspan="1" rowspan="1">72.08 *</td><td align="left" colspan="1" rowspan="1">15</td><td char="." align="char" colspan="1" rowspan="1">7.2</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic>-Octopamine</td><td align="left" colspan="1" rowspan="1">136.08</td><td align="left" colspan="1" rowspan="1">91.05 *</td><td align="left" colspan="1" rowspan="1">16</td><td char="." align="char" colspan="1" rowspan="1">3.2</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic>-Synephrine</td><td align="left" colspan="1" rowspan="1">168.10 / 150.09</td><td align="left" colspan="1" rowspan="1">150.09 * / 135.07</td><td align="left" colspan="1" rowspan="1">22 / 5</td><td char="." align="char" colspan="1" rowspan="1">3.2</td></tr><tr><td align="left" colspan="1" rowspan="1">Phenethylamine</td><td align="left" colspan="1" rowspan="1">122.09</td><td align="left" colspan="1" rowspan="1">105.07 *</td><td align="left" colspan="1" rowspan="1">8</td><td char="." align="char" colspan="1" rowspan="1">3.7</td></tr><tr><td align="left" colspan="1" rowspan="1">Tyramine</td><td align="left" colspan="1" rowspan="1">121.06</td><td align="left" colspan="1" rowspan="1">77.0395 *</td><td align="left" colspan="1" rowspan="1">20</td><td char="." align="char" colspan="1" rowspan="1">5.4</td></tr></tbody></table></table-wrap></p></sec></sec><sec id="Sec11"><title>Results</title><sec id="Sec12"><title>Caco-2 permeability assays</title><p id="Par22">Caco-2 permeability assays were performed to scale P<sub>app</sub> values to k<sub>a</sub> and fa, which were used as input values of the PBK model. Transport of the PEA analogues was studied in two directions: from the apical to the basolateral (A-B) compartment and vice versa (B-A). The efflux ratios were found within a range of 0.232 and 1.32 (Table&#160;<xref rid="Tab8" ref-type="table">8</xref> in appendix), indicating that no active efflux transporter was involved. P<sub>app</sub> values were derived from cumulative amount-time profiles, which were linear for all compounds from 0 to 60&#160;min, except for phenethylamine where it was linear from 0 to 30&#160;min. (Fig.&#160;<xref rid="Fig7" ref-type="fig">7</xref> in appendix). P<sub>app A-B</sub> values for the PEA analogues were within a range of 0.0610&#8201;&#215;&#8201;10<sup>&#8211;6</sup>&#160;cm/s for higenamine to 15.8&#8201;&#215;&#8201;10<sup>&#8211;6</sup>&#160;cm/s for &#946;-methylphenethylamine (Table&#160;<xref rid="Tab4" ref-type="table">4</xref>). The recovery after 60&#160;min for PEA in A-B experiments was 15.7&#8201;&#177;&#8201;1.51%. The recovery rates for the other PEA analogues in A-B experiments were within a range of 76.7 to 114% (Table&#160;<xref rid="Tab4" ref-type="table">4</xref>). The mean P<sub>app A-B</sub> of reference compound metoprolol in this study was 11.2&#8201;&#177;&#8201;0.197&#8201;&#215;&#8201;10<sup>&#8211;6</sup>&#160;cm/s (recovery&#8201;=&#8201;103&#8201;&#177;&#8201;2.30%), whereas the mean P<sub>app A-B</sub> of metoprolol reported in literature was 40.7&#8201;&#177;&#8201;35.5&#8201;&#215;&#8201;10<sup>&#8211;6</sup>&#160;cm/s (<italic toggle="yes">n</italic>&#8201;=&#8201;20) with values ranging from 2.3 to 140&#8201;&#215;&#8201;10<sup>&#8211;6</sup>&#160;cm/s (Table&#160;<xref rid="Tab9" ref-type="table">9</xref> in appendix) (Alsenz and Haenel <xref ref-type="bibr" rid="CR2">2003</xref>; Artursson and Karlsson <xref ref-type="bibr" rid="CR3">1991</xref>; Galkin et al. <xref ref-type="bibr" rid="CR20">2008</xref>; Gertz et al. <xref ref-type="bibr" rid="CR21">2010</xref>; Hilgendorf et al. <xref ref-type="bibr" rid="CR26">2000</xref>; Incecayir et al. <xref ref-type="bibr" rid="CR31">2013</xref>; Irvine et al. <xref ref-type="bibr" rid="CR32">1999</xref>; Kerns et al. <xref ref-type="bibr" rid="CR36">2004</xref>; Lee et al. <xref ref-type="bibr" rid="CR38">2017</xref>; Lentz et al. <xref ref-type="bibr" rid="CR39">2000</xref>; Li et al. <xref ref-type="bibr" rid="CR40">2007</xref>; Neuhoff et al. <xref ref-type="bibr" rid="CR44">2003</xref>; Palm et al. <xref ref-type="bibr" rid="CR48">1996</xref>; Punt et al. <xref ref-type="bibr" rid="CR53">2021a</xref>; Skolnik et al. <xref ref-type="bibr" rid="CR60">2010</xref>; Teksin et al. <xref ref-type="bibr" rid="CR64">2010</xref>; Vaithianathan et al. <xref ref-type="bibr" rid="CR65">2015</xref>; Yang et al. <xref ref-type="bibr" rid="CR69">2007</xref>; Yazdanian et al. <xref ref-type="bibr" rid="CR70">1998</xref>; Zhu et al. <xref ref-type="bibr" rid="CR72">2002</xref>). The P<sub>app A-B</sub> values of the PEAs were corrected for this interlaboratory difference before scaling them to k<sub>a</sub> and fa (Table&#160;<xref rid="Tab4" ref-type="table">4</xref>).<table-wrap id="Tab4" position="float" orientation="portrait"><label>Table&#160;4</label><caption><p>Mean apparent permeability (<italic toggle="yes">P</italic><sub><italic toggle="yes">app A-B</italic></sub><italic toggle="yes">&#8201;&#177;&#8201;SD</italic>) values and recovery rates&#8201;&#177;&#8201;SD derived from the Caco-2 permeability assays; <italic toggle="yes">P</italic><sub><italic toggle="yes">app A-B</italic></sub> values are corrected for the difference between <italic toggle="yes">P</italic><sub><italic toggle="yes">app A-B</italic></sub> of reference compound metoprolol in this study and as reported in literature; the corrected P<sub>app A-B</sub> values are scaled to absorption rate constants (k<sub>a</sub>) and fraction absorbed (fa) values</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"><italic toggle="yes">Compound</italic></th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic><sub><italic toggle="yes">app A-B</italic></sub><break/><italic toggle="yes">(</italic>&#215;&#8201;<italic toggle="yes">10</italic><sup><italic toggle="yes">&#8211;6</italic></sup><italic toggle="yes">&#160;cm/s)</italic></th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">Recovery</italic><break/><italic toggle="yes">(%)</italic></th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic><sub><italic toggle="yes">app A-B</italic></sub><italic toggle="yes"> corrected</italic><break/><italic toggle="yes">(</italic>&#215;&#8201;<italic toggle="yes">10</italic><sup><italic toggle="yes">&#8211;6</italic></sup><italic toggle="yes">&#160;cm/s)</italic></th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">k</italic><sub><italic toggle="yes">a</italic></sub><break/><italic toggle="yes">(/h)</italic></th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">fa</italic></th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">&#946;-Methylphenethylamine</td><td char="&#xB1;" align="left" colspan="1" rowspan="1">15.8&#8201;&#177;&#8201;1.47</td><td char="&#xB1;" align="left" colspan="1" rowspan="1">80.9&#8201;&#177;&#8201;3.27</td><td char="." align="char" colspan="1" rowspan="1">57.6</td><td char="." align="char" colspan="1" rowspan="1">3.79</td><td char="." align="char" colspan="1" rowspan="1">1.00</td></tr><tr><td align="left" colspan="1" rowspan="1">Dimethylphenethylamine</td><td char="&#xB1;" align="left" colspan="1" rowspan="1">14.7&#8201;&#177;&#8201;0.244</td><td char="&#xB1;" align="left" colspan="1" rowspan="1">76.7&#8201;&#177;&#8201;0.06</td><td char="." align="char" colspan="1" rowspan="1">53.5</td><td char="." align="char" colspan="1" rowspan="1">3.66</td><td char="." align="char" colspan="1" rowspan="1">1.00</td></tr><tr><td align="left" colspan="1" rowspan="1">Halostachine</td><td char="&#xB1;" align="left" colspan="1" rowspan="1">13.1&#8201;&#177;&#8201;0.144</td><td char="&#xB1;" align="left" colspan="1" rowspan="1">84.0&#8201;&#177;&#8201;3.18</td><td char="." align="char" colspan="1" rowspan="1">47.8</td><td char="." align="char" colspan="1" rowspan="1">3.46</td><td char="." align="char" colspan="1" rowspan="1">1.00</td></tr><tr><td align="left" colspan="1" rowspan="1">Higenamine</td><td char="&#xB1;" align="left" colspan="1" rowspan="1">0.0610&#8201;&#177;&#8201;0.0351</td><td char="&#xB1;" align="left" colspan="1" rowspan="1">104&#8201;&#177;&#8201;0.35</td><td char="." align="char" colspan="1" rowspan="1">0.223</td><td char="." align="char" colspan="1" rowspan="1">0.246</td><td char="." align="char" colspan="1" rowspan="1">0.860</td></tr><tr><td align="left" colspan="1" rowspan="1">Hordenine</td><td char="&#xB1;" align="left" colspan="1" rowspan="1">13.0&#8201;&#177;&#8201;0.192</td><td char="&#xB1;" align="left" colspan="1" rowspan="1">96.7&#8201;&#177;&#8201;1.27</td><td char="." align="char" colspan="1" rowspan="1">47.3</td><td char="." align="char" colspan="1" rowspan="1">3.46</td><td char="." align="char" colspan="1" rowspan="1">1.00</td></tr><tr><td align="left" colspan="1" rowspan="1">Isopropyloctopamine</td><td char="&#xB1;" align="left" colspan="1" rowspan="1">0.703&#8201;&#177;&#8201;0.0410</td><td char="&#xB1;" align="left" colspan="1" rowspan="1">79.8&#8201;&#177;&#8201;2.19</td><td char="." align="char" colspan="1" rowspan="1">2.56</td><td char="." align="char" colspan="1" rowspan="1">0.818</td><td char="." align="char" colspan="1" rowspan="1">0.994</td></tr><tr><td align="left" colspan="1" rowspan="1">Methylsynephrine</td><td char="&#xB1;" align="left" colspan="1" rowspan="1">0.353&#8201;&#177;&#8201;0.215</td><td char="&#xB1;" align="left" colspan="1" rowspan="1">114&#8201;&#177;&#8201;8.39</td><td char="." align="char" colspan="1" rowspan="1">1.30</td><td char="." align="char" colspan="1" rowspan="1">0.563</td><td char="." align="char" colspan="1" rowspan="1">0.971</td></tr><tr><td align="left" colspan="1" rowspan="1">Methyltyramine</td><td char="&#xB1;" align="left" colspan="1" rowspan="1">0.344&#8201;&#177;&#8201;0.0965</td><td char="&#xB1;" align="left" colspan="1" rowspan="1">87.1&#8201;&#177;&#8201;9.14</td><td char="." align="char" colspan="1" rowspan="1">1.26</td><td char="." align="char" colspan="1" rowspan="1">0.576</td><td char="." align="char" colspan="1" rowspan="1">0.981</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic>-Octopamine</td><td char="&#xB1;" align="left" colspan="1" rowspan="1">0.164&#8201;&#177;&#8201;0.0701</td><td char="&#xB1;" align="left" colspan="1" rowspan="1">98.9&#8201;&#177;&#8201;1.77</td><td char="." align="char" colspan="1" rowspan="1">0.584</td><td char="." align="char" colspan="1" rowspan="1">0.395</td><td char="." align="char" colspan="1" rowspan="1">0.947</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic>-Synephrine</td><td char="&#xB1;" align="left" colspan="1" rowspan="1">0.951&#8201;&#177;&#8201;0.497</td><td char="&#xB1;" align="left" colspan="1" rowspan="1">109&#8201;&#177;&#8201;1.48</td><td char="." align="char" colspan="1" rowspan="1">3.47</td><td char="." align="char" colspan="1" rowspan="1">0.951</td><td char="." align="char" colspan="1" rowspan="1">0.997</td></tr><tr><td align="left" colspan="1" rowspan="1">Phenethylamine</td><td char="&#xB1;" align="left" colspan="1" rowspan="1">2.88&#8201;&#177;&#8201;0.220</td><td char="&#xB1;" align="left" colspan="1" rowspan="1">15.7&#8201;&#177;&#8201;1.51</td><td char="." align="char" colspan="1" rowspan="1">10.5</td><td char="." align="char" colspan="1" rowspan="1">1.64</td><td char="." align="char" colspan="1" rowspan="1">1.00</td></tr><tr><td align="left" colspan="1" rowspan="1">Tyramine</td><td char="&#xB1;" align="left" colspan="1" rowspan="1">2.38&#8201;&#177;&#8201;1.186</td><td char="&#xB1;" align="left" colspan="1" rowspan="1">114&#8201;&#177;&#8201;11.2</td><td char="." align="char" colspan="1" rowspan="1">8.70</td><td char="." align="char" colspan="1" rowspan="1">1.50</td><td char="." align="char" colspan="1" rowspan="1">1.00</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec13"><title>In vitro hepatic clearance by human liver S9 (HLS9)</title><p id="Par23">In vitro intrinsic hepatic clearance of the PEA analogues by HLS9 was determined in this study to scale to hepatic metabolic clearance (CL<sub>met</sub>), which was used as the input value of the PBK model. The compound depletion curves with the corresponding elimination rate constants (<italic toggle="yes">k</italic>) are presented in Fig.&#160;<xref rid="Fig8" ref-type="fig">8</xref> in the appendix. The <italic toggle="yes">k</italic> values of incubation with HLS9 and co-factor mix were used to calculate the CL<sub>int</sub> values, which are shown in Table&#160;<xref rid="Tab5" ref-type="table">5</xref>. The apparent in vitro CL<sub>int</sub> (CL<sub>int app</sub>) values range from 1.49&#160;&#181;L/min/mg protein for methylsynephrine to 241 &#181;L/min/mg protein for PEA. These values are corrected for unspecific protein binding in the HLS9 incubation by using the correction method (Hallifax and Houston <xref ref-type="bibr" rid="CR24">2006</xref>). The predicted unbound fractions vary from 0.810 for methylsynephrine to 0.990 for phenethylamine, which results in corrected CL<sub>int</sub> values (CL<sub>int,u</sub>) that did not differ more than 20% from the uncorrected values (Table&#160;<xref rid="Tab5" ref-type="table">5</xref>). The CL<sub>int, u</sub> was scaled to a whole liver, after which the hepatic metabolic clearance (CL<sub>met</sub>) was modelled (Table&#160;<xref rid="Tab5" ref-type="table">5</xref>). The CL<sub>met</sub> was the highest for phenethylamine (2598 L/h) and was the lowest for methylsynephrine (19.7 L/h). &#946;-methylphenethylamine, dimethylphenethylamine, halostachine, methyltyramine, <italic toggle="yes">p</italic>-octopamine, <italic toggle="yes">p</italic>-synephrine, phenethylamine and tyramine were also metabolized in incubations without co-factor mix.<table-wrap id="Tab5" position="float" orientation="portrait"><label>Table&#160;5</label><caption><p>In vitro <italic toggle="yes">apparent intrinsic clearance (CL</italic><sub><italic toggle="yes">int app</italic></sub><italic toggle="yes">), predicted unbound HLS9 fractions and intrinsic clearance corrected for unspecific protein (HLS9) binding (CL</italic><sub><italic toggle="yes">int, u</italic></sub><italic toggle="yes">)</italic></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Compound</th><th align="left" colspan="1" rowspan="1">In vitro CL<sub>int app</sub> (&#181;L/min/mg protein)</th><th align="left" colspan="1" rowspan="1">Predicted fraction unbound in incubation</th><th align="left" colspan="1" rowspan="1">In vitro CL<sub>int,u</sub> (&#181;L/min/mg protein)</th><th align="left" colspan="1" rowspan="1">Predicted intrinsic hepatic metabolic clearance CL<sub>met</sub> (L/hr)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">&#946;-methylphenethylamine</td><td align="left" colspan="1" rowspan="1">12.1</td><td char="." align="char" colspan="1" rowspan="1">0.930</td><td align="left" colspan="1" rowspan="1">13.0</td><td align="left" colspan="1" rowspan="1">139</td></tr><tr><td align="left" colspan="1" rowspan="1">Dimethylphenethylamine</td><td align="left" colspan="1" rowspan="1">20.0</td><td char="." align="char" colspan="1" rowspan="1">0.870</td><td align="left" colspan="1" rowspan="1">23.0</td><td align="left" colspan="1" rowspan="1">245</td></tr><tr><td align="left" colspan="1" rowspan="1">Halostachine</td><td align="left" colspan="1" rowspan="1">37.4</td><td char="." align="char" colspan="1" rowspan="1">0.960</td><td align="left" colspan="1" rowspan="1">39.0</td><td align="left" colspan="1" rowspan="1">416</td></tr><tr><td align="left" colspan="1" rowspan="1">Higenamine</td><td align="left" colspan="1" rowspan="1">22.0</td><td char="." align="char" colspan="1" rowspan="1">0.900</td><td align="left" colspan="1" rowspan="1">24.4</td><td align="left" colspan="1" rowspan="1">261</td></tr><tr><td align="left" colspan="1" rowspan="1">Hordenine</td><td align="left" colspan="1" rowspan="1">2.20</td><td char="." align="char" colspan="1" rowspan="1">0.870</td><td align="left" colspan="1" rowspan="1">2.53</td><td align="left" colspan="1" rowspan="1">27.0</td></tr><tr><td align="left" colspan="1" rowspan="1">Isopropyloctopamine</td><td align="left" colspan="1" rowspan="1">2.15</td><td char="." align="char" colspan="1" rowspan="1">0.840</td><td align="left" colspan="1" rowspan="1">2.56</td><td align="left" colspan="1" rowspan="1">27.3</td></tr><tr><td align="left" colspan="1" rowspan="1">Methylsynephrine</td><td align="left" colspan="1" rowspan="1">1.49</td><td char="." align="char" colspan="1" rowspan="1">0.810</td><td align="left" colspan="1" rowspan="1">1.84</td><td align="left" colspan="1" rowspan="1">19.7</td></tr><tr><td align="left" colspan="1" rowspan="1">Methyltyramine</td><td align="left" colspan="1" rowspan="1">118</td><td char="." align="char" colspan="1" rowspan="1">0.970</td><td align="left" colspan="1" rowspan="1">122</td><td align="left" colspan="1" rowspan="1">1303</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic>-Octopamine</td><td align="left" colspan="1" rowspan="1">6.05</td><td char="." align="char" colspan="1" rowspan="1">0.860</td><td align="left" colspan="1" rowspan="1">7.06</td><td align="left" colspan="1" rowspan="1">75.4</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic>-Synephrine</td><td align="left" colspan="1" rowspan="1">11.9</td><td char="." align="char" colspan="1" rowspan="1">0.910</td><td align="left" colspan="1" rowspan="1">13.1</td><td align="left" colspan="1" rowspan="1">140</td></tr><tr><td align="left" colspan="1" rowspan="1">Phenethylamine</td><td align="left" colspan="1" rowspan="1">241</td><td char="." align="char" colspan="1" rowspan="1">0.990</td><td align="left" colspan="1" rowspan="1">243</td><td align="left" colspan="1" rowspan="1">2598</td></tr><tr><td align="left" colspan="1" rowspan="1">Tyramine</td><td align="left" colspan="1" rowspan="1">77.2</td><td char="." align="char" colspan="1" rowspan="1">0.980</td><td align="left" colspan="1" rowspan="1">78.8</td><td align="left" colspan="1" rowspan="1">841</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec14"><title>Sensitivity analysis</title><p id="Par24">A local sensitivity analysis was performed to study the influence of the PBK model input parameters on the modelled maximal venous plasma concentrations (C<sub>max plasma venous</sub>) at an oral dose of 1&#160;mg/kg bw. The NSCs obtained from this analysis for each compound are presented in Fig.&#160;<xref rid="Fig9" ref-type="fig">9</xref> of the appendix. Figure&#160;<xref rid="Fig2" ref-type="fig">2</xref> shows the NSCs of the most influential input parameters for all studied PEA analogues. Parameters that affected C<sub>max plasma venous</sub> could be related to intestinal absorption (fa and ka) and hepatic metabolic clearance (CL<sub>int</sub>, fuinc, fuliver, FVli, SF and FQ<sub>h</sub>). The NSCs of most of the parameters related to hepatic metabolic clearance were increasing for compounds with increasing modelled clearance rates (CL<sub>met</sub>), with the exception of the FQh (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>). Other parameters that were critical included the fractional muscle, kidney, brain and rest tissue blood flow (FQmu, FQki, FQbr and FQre). The influence of input parameter fa was the same for all studied compounds (NSC&#8201;=&#8201;1.00&#8201;&#177;&#8201;0.0000578).<fig id="Fig2" position="float" orientation="portrait"><label>Fig.&#160;2</label><caption><p>Normalised sensitivity coefficients (NSCs) of the C<sub>max plasma venous</sub> simulations to the most critical input parameters for all studied phenethylamine (PEA) analogues at an oral dose of 1&#160;mg/kg bw; for each parameter, data points of the 12 different PEA analogues are shown; FQmu, fractional muscle blood flow; FQh, fractional hepatic blood flow (venous side); FQki, fractional kidney blood flow; FQbr, fractional brain blood flow; FQre, fractional tissue blood flow rest of body; FVli, fractional liver volume; fuliver, fraction unbound in liver; Clint, in vitro intrinsic hepatic metabolic clearance; fuinc, fraction unbound in the in vitro liver S9 incubation; SF, scaling factor for mg liver S9 per gram liver; fa, fraction absorbed; ka, absorption rate constant</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO2" position="float" orientation="portrait" xlink:href="204_2025_3992_Fig2_HTML.jpg"/></fig><fig id="Fig3" position="float" orientation="portrait"><label>Fig.&#160;3</label><caption><p>Correlations of Normalized Sensitivity Coefficients (NSCs) and the modelled intrinsic hepatic metabolic intrinsic clearance (CL<sub>met</sub>) for the NSCs of <bold>(A)</bold> CLint (=&#8201;in vitro intrinsic hepatic metabolic clearance), <bold>(B)</bold> FQh (=&#8201;fractional hepatic blood flow, venous side), <bold>(C)</bold> FVli (=&#8201;fractional liver volume), <bold>(D)</bold> fuliver (=&#8201;fraction unbound in liver), <bold>(E)</bold> fuinc (=&#8201;fraction unbound in the in vitro liver S9 incubation) and <bold>(F)</bold> SF (=&#8201;scaling factor for mg liver S9 per gram liver)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO3" position="float" orientation="portrait" xlink:href="204_2025_3992_Fig3_HTML.jpg"/></fig></p></sec><sec id="Sec15"><title>PBK model evaluation</title><p id="Par25">The predictive performance of the PBK model was evaluated by comparing the C<sub>plasma venous</sub>-time profiles of higenamine and tyramine with observed plasma concentrations in humans (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>). In the case of tyramine, there was a 3.78-fold over-prediction of the C<sub>max plasma</sub> compared to the observed average (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>A). However, the modelled C<sub>max plasma</sub> of 1.56&#160;&#181;mol/L was within the range of the observed concentrations in all 88 participants of the study, which was from 0.00729 to 2.02&#160;&#181;mol/L (Rafehi et al. <xref ref-type="bibr" rid="CR56">2019</xref>). A PBK model with an intravenous infusion of higenamine was built to evaluate the elimination phase of higenamine by the PBK model. The modelled plasma concentration of higenamine in the first part of the elimination phase, which occurred from 0.20 to 0.45 hours, was similar to the observed concentrations from the study of (Feng et al. <xref ref-type="bibr" rid="CR18">2012</xref>) (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>B). An overestimation by the PBK model can be seen at the final part of the elimination phase, since the observed average plasma concentration at t&#8201;=&#8201;0.70&#160;h is 0.5&#160;ng/mL, while the modelled concentration 5.58&#160;ng/mL is .<fig id="Fig4" position="float" orientation="portrait"><label>Fig.&#160;4</label><caption><p>PBK model evaluation; <bold>(A)</bold> mean observed&#8201;&#177;&#8201;SD (black dots) (n&#8201;=&#8201;88) and simulated (red line) plasma concentrations of tyramine in humans after an oral dose of 5.7&#160;mg/kg bw (Rafehi et al. <xref ref-type="bibr" rid="CR56">2019</xref>); <bold>(B)</bold> mean observed&#8201;&#177;&#8201;SD (black dots) (n&#8201;=&#8201;10) and simulated (red line) plasma concentrations of higenamine in humans after an intravenous infusion of 0.5, 1, 2, and 4&#160;&#181;g/kg bw with an infusion duration of 3&#160;min per dose (Feng et al. <xref ref-type="bibr" rid="CR18">2012</xref>)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO4" position="float" orientation="portrait" xlink:href="204_2025_3992_Fig4_HTML.jpg"/></fig></p></sec><sec id="Sec16"><title>Simulated internal concentrations</title><p id="Par26">The developed PBK model with oral dosing was used to predict the plasma concentrations of PEA and its analogues after an oral dose of 1&#160;mg/kg bw (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>). The predicted tissue:plasma partition coefficients that were used as input parameters are presented as supplementary data (InputParameters.csv). The C<sub>max plasma venous</sub> of the studied compounds ranged from 0.0870&#160;&#181;M for methyltyramine to 2.95&#160;&#181;M for hordenine (Table&#160;<xref rid="Tab6" ref-type="table">6</xref>).<fig id="Fig5" position="float" orientation="portrait"><label>Fig.&#160;5</label><caption><p>Simulated plasma concentration&#8211;time profiles of the studied phenethylamine analogues at an oral dose of 1&#160;mg/kg bw</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO5" position="float" orientation="portrait" xlink:href="204_2025_3992_Fig5_HTML.jpg"/></fig><table-wrap id="Tab6" position="float" orientation="portrait"><label>Table&#160;6</label><caption><p>Simulated maximal plasma concentrations in the venous plasma compartment (C<sub>max, plasma venous</sub>) at an oral dose of 1&#160;mg/kg bw</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Compound</th><th align="left" colspan="1" rowspan="1">C<sub>max, plasma venous</sub> (&#181;M)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">&#946;-methylphenethylamine</td><td char="." align="char" colspan="1" rowspan="1">2.20</td></tr><tr><td align="left" colspan="1" rowspan="1">Dimethylphenethylamine</td><td char="." align="char" colspan="1" rowspan="1">1.50</td></tr><tr><td align="left" colspan="1" rowspan="1">Halostachine</td><td char="." align="char" colspan="1" rowspan="1">0.832</td></tr><tr><td align="left" colspan="1" rowspan="1">Higenamine</td><td char="." align="char" colspan="1" rowspan="1">0.161</td></tr><tr><td align="left" colspan="1" rowspan="1">Hordenine</td><td char="." align="char" colspan="1" rowspan="1">2.95</td></tr><tr><td align="left" colspan="1" rowspan="1">Isopropyloctopamine</td><td char="." align="char" colspan="1" rowspan="1">1.43</td></tr><tr><td align="left" colspan="1" rowspan="1">Methylsynephrine</td><td char="." align="char" colspan="1" rowspan="1">1.48</td></tr><tr><td align="left" colspan="1" rowspan="1">Methyltyramine</td><td char="." align="char" colspan="1" rowspan="1">0.0870</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic>-Octopamine</td><td char="." align="char" colspan="1" rowspan="1">0.699</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic>-Synephrine</td><td char="." align="char" colspan="1" rowspan="1">0.722</td></tr><tr><td align="left" colspan="1" rowspan="1">Phenethylamine</td><td char="." align="char" colspan="1" rowspan="1">0.130</td></tr><tr><td align="left" colspan="1" rowspan="1">Tyramine</td><td char="." align="char" colspan="1" rowspan="1">0.274</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec17"><title>Prediction of oral equivalent effect doses</title><p id="Par27">The in vitro effect concentrations (EC<sub>50</sub>), for activation of the &#945;<sub>1A,</sub> &#945;<sub>1B,</sub> &#945;<sub>1D,</sub> &#945;<sub>2A,</sub> &#945;<sub>2B,</sub> &#946;<sub>1</sub> and &#946;<sub>2</sub> adrenergic receptor (ADR) activation and the activation of TAAR1, were obtained from our previous study (Pinckaers et al. <xref ref-type="bibr" rid="CR52">2024</xref>). These EC<sub>50</sub> values were converted to equivalent effect doses (ED<sub>50</sub>) with the PBK modelling-based reverse dosimetry approach. The predicted ED<sub>50</sub> values of PEA and its analogues for in vivo activation of the ADRs and TAAR1 are presented in Table&#160;<xref rid="Tab7" ref-type="table">7</xref>. The predicted ED<sub>50</sub> values for activation of ADR&#945;<sub>1A/B/D</sub> are within a range of 0.914 to 29.7&#160;mg/kw bw. The ED<sub>50</sub> values for activation of ADR&#945;<sub>2A</sub> by hordenine and <italic toggle="yes">p</italic>-synephrine are 234 and 139&#160;mg/kg bw, respectively. Effective doses for activation of the ADR&#946;<sub>1</sub> are the lowest of all studied receptors, with especially isopropyloctopamine and higenamine being very potent (ED<sub>50</sub>&#8201;=&#8201;0.0839 and 0.211&#160;mg/kg bw, respectively). The effective doses for activation of TAAR1 range from 0.995&#160;mg/kg bw for &#946;-methylphenethylamine to 264&#160;mg/kg bw for methyltyramine. Comparison of the predicted ED<sub>50</sub> values with reported intake values, reveals that particularly higenamine, isopropyloctopamine, &#946;-methylphenethylamine and <italic toggle="yes">p</italic>-synephrine exposure is in the same range or exceeds the predicted ED<sub>50</sub> values (Table&#160;<xref rid="Tab7" ref-type="table">7</xref>).<table-wrap id="Tab7" position="float" orientation="portrait"><label>Table&#160;7</label><caption><p>Predicted ED<sub>50</sub> values (in mg/kg bw) of phenethylamine and its analogues for ADR&#945;<sub>1A/B/D</sub>, ADR&#945;<sub>2a</sub> ADR&#946;<sub>1/2</sub> and TAAR1 based on PBK modelled maximal plasma concentrations (C<sub>max plasma venous</sub>) and reported daily doses or dose ranges (in mg/kg bw); compounds with a dash (-) did not activate the receptors in vitro at concentrations&#8201;&#8804;&#8201;300&#160;&#181;M. The reported daily intake is based on the detected amount in 1 food supplement dosage and is normalized to kg/bw based on an averaged weight individual of 70&#160;kg</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Compound</th><th align="left" colspan="1" rowspan="1">ADR&#945;<sub>1A</sub><break/>ED<sub>50</sub></th><th align="left" colspan="1" rowspan="1">ADR&#945;<sub>1B</sub><break/>ED<sub>50</sub></th><th align="left" colspan="1" rowspan="1">ADR&#945;<sub>1D</sub><break/>ED<sub>50</sub></th><th align="left" colspan="1" rowspan="1">ADR&#945;<sub>2A</sub><break/>ED<sub>50</sub></th><th align="left" colspan="1" rowspan="1">ADR&#946;<sub>1</sub><break/>ED<sub>50</sub></th><th align="left" colspan="1" rowspan="1">ADR&#946;<sub>2</sub><break/>ED<sub>50</sub></th><th align="left" colspan="1" rowspan="1">TAAR1<break/>ED<sub>50</sub></th><th align="left" colspan="1" rowspan="1">Reported daily dose<break/>(mg/kg bw)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">&#946;-methylphenethylamine</td><td char="." align="char" colspan="1" rowspan="1">&#8211;</td><td char="." align="char" colspan="1" rowspan="1">&#8211;</td><td char="." align="char" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td char="." align="char" colspan="1" rowspan="1">&#8211;</td><td char="." align="char" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">0.955</td><td align="left" colspan="1" rowspan="1">1.31&#8211;14.0 Cohen et al. (<xref ref-type="bibr" rid="CR12">2021</xref>); Cohen et al. (<xref ref-type="bibr" rid="CR11">2015b</xref>); Duiven et al. (<xref ref-type="bibr" rid="CR15">2021</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Dimethylphenethylamine</td><td char="." align="char" colspan="1" rowspan="1">&#8211;</td><td char="." align="char" colspan="1" rowspan="1">4.07</td><td char="." align="char" colspan="1" rowspan="1">5.60</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td char="." align="char" colspan="1" rowspan="1">&#8211;</td><td char="." align="char" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">14.0</td><td align="left" colspan="1" rowspan="1">0.214, 6.86 Duiven et al. (<xref ref-type="bibr" rid="CR15">2021</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Halostachine</td><td char="." align="char" colspan="1" rowspan="1">10.5</td><td char="." align="char" colspan="1" rowspan="1">1.32</td><td char="." align="char" colspan="1" rowspan="1">2.52</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td char="." align="char" colspan="1" rowspan="1">&#8211;</td><td char="." align="char" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">88.9</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">not available</italic></td></tr><tr><td align="left" colspan="1" rowspan="1">Higenamine</td><td char="." align="char" colspan="1" rowspan="1">&#8211;</td><td char="." align="char" colspan="1" rowspan="1">&#8211;</td><td char="." align="char" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td char="." align="char" colspan="1" rowspan="1">0.211</td><td char="." align="char" colspan="1" rowspan="1">2.92</td><td align="left" colspan="1" rowspan="1">6.09</td><td align="left" colspan="1" rowspan="1">0.44 1.37 Biesterbos et al. (<xref ref-type="bibr" rid="CR6">2019</xref>); Cohen et al. (<xref ref-type="bibr" rid="CR12">2021</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Hordenine</td><td char="." align="char" colspan="1" rowspan="1">&#8211;</td><td char="." align="char" colspan="1" rowspan="1">1.90</td><td char="." align="char" colspan="1" rowspan="1">11.5</td><td align="left" colspan="1" rowspan="1">234</td><td char="." align="char" colspan="1" rowspan="1">&#8211;</td><td char="." align="char" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">15.9</td><td align="left" colspan="1" rowspan="1">1.19 (Biesterbos et al. <xref ref-type="bibr" rid="CR6">2019</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Isopropyloctopamine</td><td char="." align="char" colspan="1" rowspan="1">&#8211;</td><td char="." align="char" colspan="1" rowspan="1">&#8211;</td><td char="." align="char" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td char="." align="char" colspan="1" rowspan="1">0.0839</td><td char="." align="char" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">1.26</td><td align="left" colspan="1" rowspan="1">0.557&#8211;0.990 Bovee et al. (<xref ref-type="bibr" rid="CR7">2016</xref>); Cohen et al. (<xref ref-type="bibr" rid="CR12">2021</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Methylsynephrine</td><td char="." align="char" colspan="1" rowspan="1">29.7</td><td char="." align="char" colspan="1" rowspan="1">&#8211;</td><td char="." align="char" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td char="." align="char" colspan="1" rowspan="1">16.9</td><td char="." align="char" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">0.00127 &#8211; 11.4 Pawar et al. (<xref ref-type="bibr" rid="CR50">2020</xref>); Duiven et al. (<xref ref-type="bibr" rid="CR15">2021</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Methyltyramine</td><td char="." align="char" colspan="1" rowspan="1">&#8211;</td><td char="." align="char" colspan="1" rowspan="1">&#8211;</td><td char="." align="char" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td char="." align="char" colspan="1" rowspan="1">&#8211;</td><td char="." align="char" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">264</td><td align="left" colspan="1" rowspan="1">0.0000142 &#8211; 0.371 Pawar et al. (<xref ref-type="bibr" rid="CR50">2020</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic>-Octopamine</td><td char="." align="char" colspan="1" rowspan="1">15.7</td><td char="." align="char" colspan="1" rowspan="1">5.58</td><td char="." align="char" colspan="1" rowspan="1">1.72</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td char="." align="char" colspan="1" rowspan="1">7.87</td><td char="." align="char" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">65.8</td><td align="left" colspan="1" rowspan="1">0.001 &#8211; 1.86 Biesterbos et al. (<xref ref-type="bibr" rid="CR6">2019</xref>) Pawar et al. (<xref ref-type="bibr" rid="CR50">2020</xref>) Koh et al. (<xref ref-type="bibr" rid="CR37">2021</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic>-Synephrine</td><td char="." align="char" colspan="1" rowspan="1">3.32</td><td char="." align="char" colspan="1" rowspan="1">0.914</td><td char="." align="char" colspan="1" rowspan="1">2.35</td><td align="left" colspan="1" rowspan="1">139</td><td char="." align="char" colspan="1" rowspan="1">38.8</td><td char="." align="char" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">127</td><td align="left" colspan="1" rowspan="1">0.000129 &#8211; 2.29 Biesterbos et al. (<xref ref-type="bibr" rid="CR6">2019</xref>) Pawar et al. (<xref ref-type="bibr" rid="CR50">2020</xref>) Viana et al. (<xref ref-type="bibr" rid="CR66">2016</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Phenethylamine</td><td char="." align="char" colspan="1" rowspan="1">&#8211;</td><td char="." align="char" colspan="1" rowspan="1">&#8211;</td><td char="." align="char" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td char="." align="char" colspan="1" rowspan="1">&#8211;</td><td char="." align="char" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">67.7</td><td align="left" colspan="1" rowspan="1">0.17 Biesterbos et al. (<xref ref-type="bibr" rid="CR6">2019</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Tyramine</td><td char="." align="char" colspan="1" rowspan="1">&#8211;</td><td char="." align="char" colspan="1" rowspan="1">&#8211;</td><td char="." align="char" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td char="." align="char" colspan="1" rowspan="1">&#8211;</td><td char="." align="char" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">34.7</td><td align="left" colspan="1" rowspan="1">0.0000129 &#8211; 0.0157 Pawar et al. (<xref ref-type="bibr" rid="CR50">2020</xref>) Koh et al. (<xref ref-type="bibr" rid="CR37">2021</xref>)</td></tr></tbody></table></table-wrap></p><p id="Par28">In the next step, the predicted ED<sub>50</sub> values as shown in Table&#160;<xref rid="Tab7" ref-type="table">7</xref>, of all the studied PEA analogues were related to the most potent compound in the in vitro receptor activation assays which was determined previously (Pinckaers et al. <xref ref-type="bibr" rid="CR52">2024</xref>). For activation of ADR&#945;<sub>1A</sub>, ADR&#945;<sub>1B</sub> and ADR&#945;<sub>2A</sub>, <italic toggle="yes">p</italic>-synephrine was the most potent compound in the in vitro assays. After applying the kinetics in this study, the relative difference in potency between <italic toggle="yes">p</italic>-synephrine and the other agonists became smaller (Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>A,B,D). For the activation of ADR<sub>1D</sub> a similar trend was seen, but then for the most potent agonist p-octopamine (Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>C). The results of the in vitro ADR&#946;<sub>1</sub> activation assays showed that higenamine was 3.5 times more potent than isopropyloctopamine (Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>E). However, after simulating the plasma concentrations of these compounds, the relative potency of these compounds changed. The predicted equivalent oral dose for isopropyloctopamine was 2.5 times lower than the dose of higenamine needed to reach the internal effect concentration, as a result of faster intestinal uptake (Table&#160;<xref rid="Tab4" ref-type="table">4</xref>) and slower hepatic metabolic of isopropyloctopamine (Table&#160;<xref rid="Tab5" ref-type="table">5</xref>). This change in relative potency after applying the kinetics was also observed for the activation of TAAR1. Higenamine was the most potent agonist in the in vitro TAAR1 assays. However, the doses of &#946;-methylphenethylamine and isopropyloctopamine needed to reach internal effect concentrations were 6.4 and 4.8 times lower than the dose of higenamine (Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>F), because of the higher rate and amount of intestinal absorption (Table&#160;<xref rid="Tab4" ref-type="table">4</xref>) and the lower hepatic metabolic clearance rate of &#946;-methylphenethylamine and isopropyloctopamine (Table&#160;<xref rid="Tab5" ref-type="table">5</xref>).<fig id="Fig6" position="float" orientation="portrait"><label>Fig.&#160;6</label><caption><p>Relative potencies of the studied phenethylamine analogues that activated (<bold>A</bold>) ADR&#945;<sub>1A</sub>, (<bold>B</bold>) ADR&#945;<sub>1B</sub>, (<bold>C</bold>) ADR&#945;<sub>1D</sub>, (<bold>D</bold>) ADR&#945;<sub>2A</sub>, (<bold>E</bold>) ADR&#946;<sub>1</sub> and (<bold>F</bold>) TAAR1; potencies are normalized to the most potent compound in the in vitro assay; the closed bars present the in vitro relative potencies and the open bars present the predicted in vivo potencies</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO6" position="float" orientation="portrait" xlink:href="204_2025_3992_Fig6_HTML.jpg"/></fig></p></sec></sec><sec id="Sec18"><title>Discussion</title><p id="Par29">The aim of the present study was to predict oral effective doses (ED<sub>50</sub>) for humans of phenethylamine (PEA) and its analogues, to prioritize these compounds for further risk assessment. The studied PEAs have previously been shown to activate human ADRs and TAAR1 in vitro (Pinckaers et al. <xref ref-type="bibr" rid="CR52">2024</xref>), which implies that these compounds could affect (in)directly the cardiovascular system in vivo. Plasma concentrations of the PEAs were predicted using a generic PBK model (Jones and Rowland-Yeo <xref ref-type="bibr" rid="CR34">2013</xref>) and were linked to in vitro EC<sub>50</sub> values for activation of ADR&#945;<sub>1A/B/D</sub>, ADR&#945;<sub>2A</sub>, ADR&#946;<sub>1/2</sub> and TAAR1. Consequently, in vivo ED<sub>50</sub> values were predicted by applying the reverse dosimetry approach. The predicted ED<sub>50</sub> values of the studied PEAs for activation of ADR&#945;<sub>1A/B/D</sub>, ADR&#945;<sub>2A</sub>, ADR&#946;<sub>1</sub> and TAAR1 were within a range of 0.914 to 29.7&#160;mg/kg body weight (bw), 139 to 234&#160;mg/kg bw, 0.0839 to 38.8&#160;mg/kg bw and 0.995 to 264&#160;mg/kg bw, respectively.</p><p id="Par30">To predict plasma concentrations of the PEA analogues with the PBK model, information about intestinal absorption and hepatic metabolic clearance for each of the compounds was required. These input parameters were extrapolated from experimentally collected in vitro data in the current study. Using transport studies with Caco-2 cells, the intestinal uptake rate and the intestinal fraction absorbed by the PEA analogues were extrapolated. Unlike the studied analogues, PEA itself had a poor recovery of 15.7% in the Caco-2 transport studies when it was added to the apical side of the cell culture system, whereas the recovery in the experiments studying the opposite transport direction (i.e. from the basolateral to the apical compartment) was 103%. This suggests that PEA was metabolized by Caco-2 cells, which was confirmed by the presence of the molecular ion of the deaminated product of PEA, phenylacetic acid, in medium collected from Caco-2 cells upon PEA exposure (Fig.&#160;<xref rid="Fig10" ref-type="fig">10</xref> in the appendix). It has been previously shown that PEA is a substrate of monoamine oxidase B (MAO-B) that deaminates amines and that this enzyme is active in Caco-2 cells (Obata et al. <xref ref-type="bibr" rid="CR45">2022</xref>; Vieira-Coelho et al. <xref ref-type="bibr" rid="CR67">1999</xref>) (Iwasa et al. <xref ref-type="bibr" rid="CR33">2003</xref>). Although some of the other studied PEAs are also known MAO(-A/B) substrates (e.g. tyramine and <italic toggle="yes">p</italic>-synephrine) (Balsa et al. <xref ref-type="bibr" rid="CR5">1989</xref>; Oguchi et al. <xref ref-type="bibr" rid="CR46">1981</xref>) (Suzuki et al. <xref ref-type="bibr" rid="CR63">1979</xref>), their metabolic breakdown by Caco-2 cells was not observed in this study. This could be explained by the higher affinity that PEA has for MAO compared to other PEA analogues (Balsa et al. <xref ref-type="bibr" rid="CR5">1989</xref>; Oguchi et al. <xref ref-type="bibr" rid="CR46">1981</xref>). In addition, our study shows that the apparent intrinsic clearance is the highest for PEA, which is approximately 2 to 112 times higher than the clearance of its analogues (Table&#160;<xref rid="Tab5" ref-type="table">5</xref>), which might explain the poor recovery of PEA, and not its analogues, in Caco-2 transport studies.</p><p id="Par31">The hepatic metabolic clearance was extrapolated from in vitro studies with HLS9. All PEA analogues, except higenamine, were metabolized for 34.7 to 95.5% of the total metabolic clearance, in the absence of the co-factor mix that enabled oxidation, reduction, hydrolysis, glucuronidation, sulfation and methylation. This indicates that those compounds were metabolized by enzymes that did not need externally added co-factors, such as MAO.</p><p id="Par32">The potential effects of the PEA metabolites and its analogues were not included in the current study, as this was out of our scope. Interestingly, for some of the studied PEAs it is known that they can be transformed into bioactive metabolites. For example, tyramine can be metabolized by the liver into <italic toggle="yes">p</italic>-octopamine and into dopamine (Faraj et al. <xref ref-type="bibr" rid="CR17">1979</xref>; Hiroi et al. <xref ref-type="bibr" rid="CR27">1998</xref>). Tyramine does not activate ADRs directly, whereas <italic toggle="yes">p</italic>-octopamine can activate &#945;<sub>1</sub> and &#946;<sub>1</sub> ADRs. Furthermore, <italic toggle="yes">p</italic>-octopamine and <italic toggle="yes">p</italic>-synephrine were also found to be metabolized into noradrenaline and adrenaline, respectively, by CYP2D6 in human liver microsomes (Hiroi et al. <xref ref-type="bibr" rid="CR27">1998</xref>). Hence, besides the suggested effects after the oral consumption of the studied PEAs, some of the metabolites could have additional pharmacological effects when metabolized into other bioactive molecules. The predicted intrinsic metabolic clearance of reference compound tyramine (841 L/hr), scaled from the in vitro HLS9 incubations in this study (Table&#160;<xref rid="Tab5" ref-type="table">5</xref>), was in the same range as the metabolic clearance observed in humans (792 L/hr) (Faraj et al. <xref ref-type="bibr" rid="CR17">1979</xref>). This highlights the relevance and predictive value of incorporating in vitro hepatic clearance in the PBK model. The adequacy of the in vitro hepatic clearance was also shown by comparing the predicted higenamine plasma elimination and the observed plasma elimination, which were in the same range (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>B).</p><p id="Par33">The predicted intestinal and hepatic kinetic data were integrated into the PBK model, after which the plasma concentrations were simulated. The performance of the PBK model was evaluated by comparing the predicted plasma concentration&#8211;time profiles of tyramine with observed concentrations in humans (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>A). There was a 3.78-fold over-prediction of the C<sub>max plasma</sub> of tyramine compared to the observed average, which may be explained by an overestimation of the intestinal absorption or an underestimation of the volume of distribution (Punt et al. <xref ref-type="bibr" rid="CR55">2022</xref>). Overestimations of C<sub>max plasma</sub> values are frequently observed when using generic PBK models, which might be explained by their lack of extrahepatic metabolism or active efflux transport (Punt et al. <xref ref-type="bibr" rid="CR55">2022</xref>). Interestingly, the modelled C<sub>max plasma</sub> of 1.56&#160;&#181;mol/L was still within the range of the observed concentrations (i.e. between 0.00729 and 2.02&#160;&#181;mol/L) of all 88 participants of the study. This highlights that there is high variability between humans in plasma concentrations after an oral dose of tyramine and that the generic PBK model used in our study also covers individuals with higher plasma concentrations. With regards to risk assessment of purposes, this is especially important as individuals at higher risk for the toxicological effects of these compounds should be protected.</p><p id="Par34">In the current study, a generic PBK model with standard physiological parameters was used to predict plasma concentrations and in vivo potencies of the PEA analogues (Jones and Rowland-Yeo <xref ref-type="bibr" rid="CR34">2013</xref>). The cardiac output (CO) in the used PBK model was 108.33&#160;mL/s, which represents the physiology of a resting individual (Brown et al. <xref ref-type="bibr" rid="CR9">1997</xref>; Joyner and Casey <xref ref-type="bibr" rid="CR35">2015</xref>). Physical exercise is one of the factors that influences CO and tissue perfusion, and thereby also the kinetics. The CO can increase by 29%, 52% and 362% during light, moderate and heavy exercise, respectively (Brown et al. <xref ref-type="bibr" rid="CR9">1997</xref>). On the contrary, blood flow to the liver and intestinal tissues is decreased to compensate for an increased blood flow to (cardiac) muscle and bone tissue. Exercise could therefore reduce the C<sub>max plasma</sub> but with a retained AUC, as a result of a slower hepatic metabolic breakdown. PEA and its analogues are often used as pre-workout supplements to allow intestinal absorption and effective plasma concentrations before starting the workout. This implies that the intestinal absorption occurs during resting conditions, but that the hepatic metabolic breakdown takes place during exercise. The impaired liver perfusion during exercise decreases the hepatic metabolic breakdown, which leads to plasma concentrations that could be at an effective level for a longer time compared to situations during rest. This could increase the exposure time and the associated risk of pharmacological effects and should be taken into account in future PBK modelling and risk assessment studies.</p><p id="Par35">The predicted ED<sub>50</sub> values in this study are in the same range as reported daily doses in food supplements for some of the studied PEAs (Table&#160;<xref rid="Tab7" ref-type="table">7</xref>), which implies that cardiovascular effects could be expected in vivo. Strikingly, the reported daily intake doses of isopropyloctopamine were about ten times higher than the predicted dose needed to reach plasma concentrations similar to the EC<sub>50</sub> to activate ADR&#946;<sub>1</sub>, suggesting that intake may lead to ADR&#946;<sub>1</sub> mediated effects, such as tachycardia (Alhayek and Preuss <xref ref-type="bibr" rid="CR1">2024</xref>). Adverse cardiac effects were indeed previously linked to the use of a food supplement containing isopropyloctopamine (Bovee et al. <xref ref-type="bibr" rid="CR7">2016</xref>). The use of this food supplement was associated with multiple hospitalisations and even in one case, the patient died as a result of a cardiac arrest. Also for other PEA analogues, reported daily intake doses were found to be in the same range or higher than predicted ED<sub>50</sub> values needed to reach plasma concentrations to activate ADR&#945;<sub>1A/B</sub> (<italic toggle="yes">p</italic>-synephrine), ADR&#945;<sub>1D</sub> (<italic toggle="yes">p</italic>-synephrine, <italic toggle="yes">p</italic>-octopamine), ADR&#946;<sub>1</sub> (higenamine) (Hudzik et al. <xref ref-type="bibr" rid="CR30">2020</xref>) and TAAR1 (&#946;-methylphenethylamine, isopropyloctopamine) (Table&#160;<xref rid="Tab7" ref-type="table">7</xref>). These results imply that users of food supplements containing these pharmacologically active substances may expect sympathetic activation and cardiovascular effects and could thus be at risk for (severe) adverse health effects. Hence, these compounds should be considered as high-priority compounds for further risk assessment. Our study furthermore highlights the importance of including kinetics in compound prioritization for risk assessment purposes, since the relative potencies changed for the activation of ADR&#946;<sub>1</sub> and TAAR1 when using the PBK modelling-based reverse dosimetry approach compared to prioritization based on only in vitro potencies (Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>).</p><p id="Par36">The safety regulation of food supplements containing pharmacologically active compounds in The Netherlands, and other European countries, is rather complex (Biesterbos et al. <xref ref-type="bibr" rid="CR6">2019</xref>; Czepielewska et al. <xref ref-type="bibr" rid="CR13">2018</xref>). In case the food supplement contains pharmacologically active compounds that (1) are not classified as medicinal products, (2) do not fall under the Commodity law herbal preparations &amp; Regulation (EC) No 1925/2006, (3) are not classified as novel food (Regulation EU) 2015/2283 and (4) are not proven to be unsafe (i.e. the General food law: food cannot be for sale when it is not safe, Regulation (EC) No 178/2002), it stays freely available on the market (Biesterbos et al. <xref ref-type="bibr" rid="CR6">2019</xref>). This indicates that, when there is no information available concerning pharmacological and toxicological effects, food supplements with pharmacologically active compounds can stay on the market until proven to pose a risk to human health. The Office of Risk Assessment &amp; Research of the Netherlands Food and Consumer Product Safety Authority performs those risk assessments in The Netherlands. As the list of compounds in food supplements with an unknown safety profile is growing (Czepielewska et al. <xref ref-type="bibr" rid="CR13">2018</xref>) and since there is no legal requirement to prove food safety before entering the market (Biesterbos et al. <xref ref-type="bibr" rid="CR6">2019</xref>), there is a high need for prioritization methods that can accelerate human health risk assessment. Our study shows that the use of QIVIVE of adrenergic and TAAR1 potencies using a generic PBK model (with minimal required input data to describe passive intestinal uptake, liver metabolism, partition coefficients, fraction unbound in plasma, and blood:plasma ratio) can serve as an efficient prioritization method for a whole set of chemical analogues. In case new chemical analogues with an unknown safety profile are detected in food supplements, the above-described case study can easily be expanded and applied to the particular compounds. Generic PBK models can, however, not be applied for all chemicals, since the predictive performance cannot be guaranteed. However, the use of PBK models for groups of chemical analogues offers more reliable QIVIVEs (Najjar et al. <xref ref-type="bibr" rid="CR43">2022</xref>).</p><p id="Par37">In conclusion, our study demonstrates the applicability of QIVIVE and PBK modelling as NAMs to prioritize large sets of compounds for risk assessment. Our findings suggest that the consumption of food supplements containing higenamine, isopropyloctopamine, &#946;-methylphenethylamine and <italic toggle="yes">p</italic>-synephrine could result in effective plasma concentrations to activate ADRs or TAAR1, that (in)directly affect the cardiovascular system. These PEA analogues should therefore be considered as high priority compounds for further risk assessment.</p></sec><sec id="Sec20" sec-type="supplementary-material"><title>Electronic supplementary material</title><p>Below is the link to the electronic supplementary material.<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="204_2025_3992_MOESM1_ESM.pdf" position="float" orientation="portrait"><caption><p>Supplementary file1 (PDF 43 kb)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM2" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="204_2025_3992_MOESM2_ESM.pdf" position="float" orientation="portrait"><caption><p>Supplementary file2 (PDF 35 kb)</p></caption></media></supplementary-material></p></sec></body><back><app-group><app id="App1"><sec id="Sec19"><title>Appendix</title><table-wrap id="Tab8" position="float" orientation="portrait"><label>Table&#160;8</label><caption><p><italic toggle="yes">Mean apparent permeability (P</italic><sub><italic toggle="yes">app</italic></sub>&#8201;&#177;&#8201;<italic toggle="yes">SD) values, recovery rates</italic>&#8201;&#177;&#8201;<italic toggle="yes">SD and efflux ratios derived from the</italic> in vitro <italic toggle="yes">Caco-2 permeability assays studying apical to basolateral (A-B) and basolateral to apical (B-A) transport</italic></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">
<italic toggle="yes">Compound</italic>
</th><th align="left" colspan="1" rowspan="1">
<italic toggle="yes">A-B</italic>
<break/><italic toggle="yes">P</italic><sub><italic toggle="yes">app</italic></sub><italic toggle="yes"> (</italic>&#215;&#8201;<italic toggle="yes">10</italic><sup><italic toggle="yes">&#8211;6</italic></sup><italic toggle="yes">&#160;cm/s)</italic></th><th align="left" colspan="1" rowspan="1">
<italic toggle="yes">Recovery (%)</italic>
</th><th align="left" colspan="1" rowspan="1">
<italic toggle="yes">B-A</italic>
<break/><italic toggle="yes">P</italic><sub><italic toggle="yes">app</italic></sub><italic toggle="yes"> (</italic>&#215;&#8201;<italic toggle="yes">10</italic><sup><italic toggle="yes">&#8211;6</italic></sup><italic toggle="yes">&#160;cm/s)</italic></th><th align="left" colspan="1" rowspan="1">
<italic toggle="yes">Recovery (%)</italic>
</th><th align="left" colspan="1" rowspan="1">
<italic toggle="yes">Efflux ratio</italic>
</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">&#946;-methylphenethylamine</td><td char="&#x2009;&#xB1;" align="char" colspan="1" rowspan="1">15.8&#8201;&#177;&#8201;1.47</td><td char="&#x2009;&#xB1;" align="char" colspan="1" rowspan="1">80.9&#8201;&#177;&#8201;3.27</td><td char="&#x2009;&#xB1;" align="char" colspan="1" rowspan="1">12.1&#8201;&#177;&#8201;2.02</td><td char="&#x2009;&#xB1;" align="char" colspan="1" rowspan="1">89.3&#8201;&#177;&#8201;4.46</td><td char="." align="char" colspan="1" rowspan="1">0.766</td></tr><tr><td align="left" colspan="1" rowspan="1">Dimethylphenethylamine</td><td char="&#x2009;&#xB1;" align="char" colspan="1" rowspan="1">14.7&#8201;&#177;&#8201;0.244</td><td char="&#x2009;&#xB1;" align="char" colspan="1" rowspan="1">76.7&#8201;&#177;&#8201;0.06</td><td char="&#x2009;&#xB1;" align="char" colspan="1" rowspan="1">13.1&#8201;&#177;&#8201;0.510</td><td char="&#x2009;&#xB1;" align="char" colspan="1" rowspan="1">93.3&#8201;&#177;&#8201;4.81</td><td char="." align="char" colspan="1" rowspan="1">0.891</td></tr><tr><td align="left" colspan="1" rowspan="1">Halostachine</td><td char="&#x2009;&#xB1;" align="char" colspan="1" rowspan="1">13.1&#8201;&#177;&#8201;0.144</td><td char="&#x2009;&#xB1;" align="char" colspan="1" rowspan="1">84.0&#8201;&#177;&#8201;3.18</td><td char="&#x2009;&#xB1;" align="char" colspan="1" rowspan="1">10.3&#8201;&#177;&#8201;0.649</td><td char="&#x2009;&#xB1;" align="char" colspan="1" rowspan="1">93.9&#8201;&#177;&#8201;0.0289</td><td char="." align="char" colspan="1" rowspan="1">0.786</td></tr><tr><td align="left" colspan="1" rowspan="1">Higenamine</td><td char="&#x2009;&#xB1;" align="char" colspan="1" rowspan="1">0.0610&#8201;&#177;&#8201;0.0351</td><td char="&#x2009;&#xB1;" align="char" colspan="1" rowspan="1">104&#8201;&#177;&#8201;0.35</td><td char="&#x2009;&#xB1;" align="char" colspan="1" rowspan="1">0.0612&#8201;&#177;&#8201;0.00186</td><td char="&#x2009;&#xB1;" align="char" colspan="1" rowspan="1">105&#8201;&#177;&#8201;1.06</td><td char="." align="char" colspan="1" rowspan="1">1.00</td></tr><tr><td align="left" colspan="1" rowspan="1">Hordenine</td><td char="&#x2009;&#xB1;" align="char" colspan="1" rowspan="1">13.0&#8201;&#177;&#8201;0.192</td><td char="&#x2009;&#xB1;" align="char" colspan="1" rowspan="1">96.7&#8201;&#177;&#8201;1.27</td><td char="&#x2009;&#xB1;" align="char" colspan="1" rowspan="1">11.2&#8201;&#177;&#8201;0.220</td><td char="&#x2009;&#xB1;" align="char" colspan="1" rowspan="1">107&#8201;&#177;&#8201;0.0262</td><td char="." align="char" colspan="1" rowspan="1">0.862</td></tr><tr><td align="left" colspan="1" rowspan="1">Isopropyloctopamine</td><td char="&#x2009;&#xB1;" align="char" colspan="1" rowspan="1">0.703&#8201;&#177;&#8201;0.0410</td><td char="&#x2009;&#xB1;" align="char" colspan="1" rowspan="1">79.8&#8201;&#177;&#8201;2.19</td><td char="&#x2009;&#xB1;" align="char" colspan="1" rowspan="1">0.652&#8201;&#177;&#8201;0.0444</td><td char="&#x2009;&#xB1;" align="char" colspan="1" rowspan="1">76.5&#8201;&#177;&#8201;1.27</td><td char="." align="char" colspan="1" rowspan="1">0.927</td></tr><tr><td align="left" colspan="1" rowspan="1">Methylsynephrine</td><td char="&#x2009;&#xB1;" align="char" colspan="1" rowspan="1">0.353&#8201;&#177;&#8201;0.215</td><td char="&#x2009;&#xB1;" align="char" colspan="1" rowspan="1">114&#8201;&#177;&#8201;8.39</td><td char="&#x2009;&#xB1;" align="char" colspan="1" rowspan="1">0.390&#8201;&#177;&#8201;0.202</td><td char="&#x2009;&#xB1;" align="char" colspan="1" rowspan="1">102&#8201;&#177;&#8201;11.7</td><td char="." align="char" colspan="1" rowspan="1">1.10</td></tr><tr><td align="left" colspan="1" rowspan="1">Methyltyramine</td><td char="&#x2009;&#xB1;" align="char" colspan="1" rowspan="1">0.344&#8201;&#177;&#8201;0.0965</td><td char="&#x2009;&#xB1;" align="char" colspan="1" rowspan="1">87.1&#8201;&#177;&#8201;9.14</td><td char="&#x2009;&#xB1;" align="char" colspan="1" rowspan="1">0.455&#8201;&#177;&#8201;0.156</td><td char="&#x2009;&#xB1;" align="char" colspan="1" rowspan="1">85.2&#8201;&#177;&#8201;10.4</td><td char="." align="char" colspan="1" rowspan="1">1.32</td></tr><tr><td align="left" colspan="1" rowspan="1">Metoprolol</td><td char="&#x2009;&#xB1;" align="char" colspan="1" rowspan="1">11.2&#8201;&#177;&#8201;0.197</td><td char="&#x2009;&#xB1;" align="char" colspan="1" rowspan="1">103&#8201;&#177;&#8201;2.30</td><td char="&#x2009;&#xB1;" align="char" colspan="1" rowspan="1">9.25&#8201;&#177;&#8201;0.170</td><td char="&#x2009;&#xB1;" align="char" colspan="1" rowspan="1">103&#8201;&#177;&#8201;8.60</td><td char="." align="char" colspan="1" rowspan="1">0.826</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic>-Octopamine</td><td char="&#x2009;&#xB1;" align="char" colspan="1" rowspan="1">0.164&#8201;&#177;&#8201;0.0701</td><td char="&#x2009;&#xB1;" align="char" colspan="1" rowspan="1">98.9&#8201;&#177;&#8201;1.77</td><td char="&#x2009;&#xB1;" align="char" colspan="1" rowspan="1">0.117&#8201;&#177;&#8201;0.0171</td><td char="&#x2009;&#xB1;" align="char" colspan="1" rowspan="1">109&#8201;&#177;&#8201;15.0</td><td char="." align="char" colspan="1" rowspan="1">0.713</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic>-Synephrine</td><td char="&#x2009;&#xB1;" align="char" colspan="1" rowspan="1">0.951&#8201;&#177;&#8201;0.497</td><td char="&#x2009;&#xB1;" align="char" colspan="1" rowspan="1">109&#8201;&#177;&#8201;1.48</td><td char="&#x2009;&#xB1;" align="char" colspan="1" rowspan="1">0.220&#8201;&#177;&#8201;0.0453</td><td char="&#x2009;&#xB1;" align="char" colspan="1" rowspan="1">100&#8201;&#177;&#8201;4.89</td><td char="." align="char" colspan="1" rowspan="1">0.231</td></tr><tr><td align="left" colspan="1" rowspan="1">Phenethylamine</td><td char="&#x2009;&#xB1;" align="char" colspan="1" rowspan="1">2.88&#8201;&#177;&#8201;0.220</td><td char="&#x2009;&#xB1;" align="char" colspan="1" rowspan="1">15.7&#8201;&#177;&#8201;1.51</td><td char="&#x2009;&#xB1;" align="char" colspan="1" rowspan="1">1.95&#8201;&#177;&#8201;1.04</td><td char="&#x2009;&#xB1;" align="char" colspan="1" rowspan="1">103&#8201;&#177;&#8201;3.36</td><td char="." align="char" colspan="1" rowspan="1">0.677</td></tr><tr><td align="left" colspan="1" rowspan="1">Tyramine</td><td char="&#x2009;&#xB1;" align="char" colspan="1" rowspan="1">2.38&#8201;&#177;&#8201;1.186</td><td char="&#x2009;&#xB1;" align="char" colspan="1" rowspan="1">114&#8201;&#177;&#8201;11.2</td><td char="&#x2009;&#xB1;" align="char" colspan="1" rowspan="1">1.13&#8201;&#177;&#8201;0.670</td><td char="&#x2009;&#xB1;" align="char" colspan="1" rowspan="1">84.0&#8201;&#177;&#8201;6.25</td><td char="." align="char" colspan="1" rowspan="1">0.475</td></tr></tbody></table></table-wrap><table-wrap id="Tab9" position="float" orientation="portrait"><label>Table&#160;9</label><caption><p>P<sub>app A-B</sub> values of metoprolol in Caco-2 permeability assays as reported in literature (average&#8201;=&#8201;40.7&#8201;&#215;&#8201;10<sup>&#8211;6</sup>&#160;cm/sec&#8201;&#177;&#8201;35.5; coefficient of variation&#8201;=&#8201;87.3%; n&#8201;=&#8201;20)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">P<sub>app</sub>&#8201;&#215;&#8201;10<sup>&#8211;6</sup> (cm/sec)</th><th align="left" colspan="1" rowspan="1">References</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">8.19</td><td align="left" colspan="1" rowspan="1">Lee et al. (<xref ref-type="bibr" rid="CR38">2017</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">31.8</td><td align="left" colspan="1" rowspan="1">Alsenz and Haenel (<xref ref-type="bibr" rid="CR2">2003</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">140</td><td align="left" colspan="1" rowspan="1">Irvine et al. (<xref ref-type="bibr" rid="CR32">1999</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">33.2</td><td align="left" colspan="1" rowspan="1">Li et al. (<xref ref-type="bibr" rid="CR40">2007</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">23.7</td><td align="left" colspan="1" rowspan="1">Zhu et al. (<xref ref-type="bibr" rid="CR72">2002</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">17.7</td><td align="left" colspan="1" rowspan="1">Skolnik et al. (<xref ref-type="bibr" rid="CR60">2010</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">2.30</td><td align="left" colspan="1" rowspan="1">Kerns et al. (<xref ref-type="bibr" rid="CR36">2004</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">40.0</td><td align="left" colspan="1" rowspan="1">Teksin et al. (<xref ref-type="bibr" rid="CR64">2010</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">22.5</td><td align="left" colspan="1" rowspan="1">Incecayir et al. (<xref ref-type="bibr" rid="CR31">2013</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">36.9</td><td align="left" colspan="1" rowspan="1">Yang et al. (<xref ref-type="bibr" rid="CR69">2007</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">21.2</td><td align="left" colspan="1" rowspan="1">Vaithianathan et al. (<xref ref-type="bibr" rid="CR65">2015</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">60.1</td><td align="left" colspan="1" rowspan="1">Punt et al. (<xref ref-type="bibr" rid="CR53">2021a</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">29.0</td><td align="left" colspan="1" rowspan="1">Galkin et al. (<xref ref-type="bibr" rid="CR20">2008</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">18.8</td><td align="left" colspan="1" rowspan="1">Hilgendorf et al. (<xref ref-type="bibr" rid="CR26">2000</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">23.7</td><td align="left" colspan="1" rowspan="1">Yazdanian et al. (<xref ref-type="bibr" rid="CR70">1998</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">27.0</td><td align="left" colspan="1" rowspan="1">Artursson and Karlsson (<xref ref-type="bibr" rid="CR3">1991</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">91.9</td><td align="left" colspan="1" rowspan="1">Palm et al. (<xref ref-type="bibr" rid="CR48">1996</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">41.9</td><td align="left" colspan="1" rowspan="1">Lentz et al. (<xref ref-type="bibr" rid="CR39">2000</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">116</td><td align="left" colspan="1" rowspan="1">Neuhoff et al. (<xref ref-type="bibr" rid="CR44">2003</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">28.1</td><td align="left" colspan="1" rowspan="1">Gertz et al. (<xref ref-type="bibr" rid="CR21">2010</xref>)</td></tr></tbody></table></table-wrap><fig id="Fig7" position="float" orientation="portrait"><label>Fig.&#160;7</label><caption><p>In vitro transport of Phenethylamine (analogues) and model compound metoprolol across Caco-2 cell layers at a starting concentration of 10&#160;&#181;M<bold>; c</bold>umulative amount of <bold>(A)</bold> &#946;-methylphenethylamine, <bold>(B)</bold> dimethylphenethylamine, <bold>(C)</bold> halostachine, <bold>(D)</bold> higenamine, <bold>(E)</bold> hordenine, <bold>(F)</bold> isopropyloctopamine, <bold>(G)</bold> methylsynephrine, <bold>(H)</bold> methyltyramine, <bold>(I)</bold> metoprolol, <bold>(J)</bold> p-octopamine, <bold>(K)</bold> p-synephrine, <bold>(L)</bold> phenethylamine and <bold>(M)</bold> tyramine in the basolateral compartment (for A-B studies*) or in the apical compartment (for B-A studies**) during transport after apical (for A-B) or basolateral (for B-A) exposure to 10&#160;&#181;M of each compound; samples were taken from the receiver compartment (B for A-B and A for B-A studies) after 15, 30 and 60&#160;min; the amount of compound (in pmol) was quantified using LC&#8211;MS/MS; data are presented as mean values&#8201;&#177;&#8201;SD from duplicate wells. * A-B studies: transport direction from the apical to the basolateral compartment was studied by adding the compound to the apical side at the start of the experiment. ** B-A studies: transport direction from the basolateral to the apical compartment was studied by adding the compound to the basolateral side at the start of the experiment</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="MO7" orientation="portrait" xlink:href="204_2025_3992_Fig7_HTML.jpg"/></fig><fig id="Fig8" position="float" orientation="portrait"><label>Fig.&#160;8</label><caption><p>Compound depletion of a starting concentration of 1&#160;&#181;M of <bold>(A)</bold> &#946;-methylphenethylamine, <bold>(B)</bold> dimethylphenethylamine, <bold>(C)</bold> halostachine, <bold>(D)</bold> higenamine, <bold>(E)</bold> hordenine, <bold>(F)</bold> isopropyloctopamine, <bold>(G)</bold> methylsynephrine, <bold>(H)</bold> methyltyramine, <bold>(I)</bold> p-octopamine, <bold>(J)</bold> p-synephrine, <bold>(K)</bold> phenethylamine and <bold>(L)</bold> tyramine in incubations with human liver S9 (HSL9) and co-factor mix (=&#8201;full reaction mix; <bold>dots</bold>), in incubations with co-factor mix and without HLS9 (=&#8201;w/o human liver S9; <bold>squares</bold>) and in incubations with HLS9 and without co-factor mix (=&#8201;w/o co-factor mix; <bold>triangles</bold>); data points (&#177;&#8201;SD) are shown as the natural logarithm (Ln) of the percentage of the parent compound at time point zero; K represents the elimination rate constant (/min) derived from the slope of compound depletion in full reaction mix incubations&#160;</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="MO8" orientation="portrait" xlink:href="204_2025_3992_Fig8_HTML.jpg"/></fig><fig id="Fig9" position="float" orientation="portrait"><label>Fig.&#160;9</label><caption><p>Normalised sensitivity coefficients (NSCs) of the C<sub>max plasma venous</sub> simulations to the critical input parameters for all studied phenethylamine (PEA) analogues at an oral dose of 1&#160;mg/kg bw; (A) &#946;-methylphenethylamine, (B) dimethylphenethylamine, (C) halostachine, (D) higenamine, (E) hordenine, (F) isopropyloctopamine, (G) methylsynephrine, (H) methyltyramine, (I) phenethylamine, (J) p-octopamine, (K) p-synephrine and (L) tyramine. FQre&#8201;=&#8201;fractional tissue blood flow rest of body, FQte&#8201;=&#8201;fractional testes blood, FQsp&#8201;=&#8201;fractional spleen blood flow, FQmu&#8201;=&#8201;fractional muscle blood flow, FQh&#8201;=&#8201;fractional hepatic blood flow, FQki&#8201;=&#8201;fractional kidney blood flow, FQhe&#8201;=&#8201;fractional heart blood flow, FQgu&#8201;=&#8201;fractional gut blood flow, FQbr&#8201;=&#8201;fractional brain blood flow, FQbo&#8201;=&#8201;fractional bone blood flow, FQad&#8201;=&#8201;fractional adipose tissue blood flow, CO&#8201;=&#8201;cardiac output, FVre&#8201;=&#8201;fractional volume rest of body, FVpl&#8201;=&#8201;fractional volume plasma, FVar&#8201;=&#8201;fractional volume arterial blood, FVve&#8201;=&#8201;fractional volume venous blood, FVte&#8201;=&#8201;fractional volume testes, FVsp&#8201;=&#8201;fractional volume spleen, FVsk&#8201;=&#8201;fractional volume skin, FVmu&#8201;=&#8201;fractional volume muscle, FVlu&#8201;=&#8201;fractional volume lung, FVli&#8201;=&#8201;fractional volume liver, FVki&#8201;=&#8201;fractional volume kidney, FVhe&#8201;=&#8201;fractional volume heart, FVgu&#8201;=&#8201;fractional volume gut, FVbr&#8201;=&#8201;fractional volume brain, FVbo&#8201;=&#8201;fractional volume bone, FVad&#8201;=&#8201;fractional volume adipose tissue, BW&#8201;=&#8201;body weight, BP&#8201;=&#8201;blood/plasma ratio, fuliver&#8201;=&#8201;fraction unbound liver, fup&#8201;=&#8201;fraction unbound in plasma, CLint&#8201;=&#8201;intrinsic clearance, fuinc&#8201;=&#8201;fraction unbound in human liver S9 incubation, SF&#8201;=&#8201;scaling factor of human liver S9 to a whole human liver, Kpre&#8201;=&#8201;rest of body:plasma partition coefficient, Kpte&#8201;=&#8201;testes:plasma partition coefficient, Kpsp&#8201;=&#8201;spleen:plasma partition coefficient, Kpsk&#8201;=&#8201;skin:plasma partition coefficient, Kpmu&#8201;=&#8201;muscle:plasma partition coefficient, Kplu&#8201;=&#8201;lung:plasma partition coefficient, Kpli&#8201;=&#8201;liver:plasma partition coefficient, Kpki&#8201;=&#8201;kidney:plasma partition coefficient, Kphe&#8201;=&#8201;heart:plasma partition coefficient, Kpgu&#8201;=&#8201;gut:plasma partition coefficient, Kpbr&#8201;=&#8201;brain:plasma partition coefficient, Kpbo&#8201;=&#8201;bone:plasma partition coefficient, Kpad&#8201;=&#8201;adipose:plasma partition coefficient, fa&#8201;=&#8201;fraction absorbed, ka&#8201;=&#8201;absorption rate constant</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="d33e3612" orientation="portrait" xlink:href="204_2025_3992_Fig9a_HTML.jpg"/><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="d33e3613" orientation="portrait" xlink:href="204_2025_3992_Fig9b_HTML.jpg"/><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="d33e3614" orientation="portrait" xlink:href="204_2025_3992_Fig9c_HTML.jpg"/></fig><fig id="Fig10" position="float" orientation="portrait"><label>Fig.&#160;10</label><caption><p>LC&#8211;MS analysis of the deaminated product of phenethylamine: phenylacetic acid (m/z 137.046) in medium collected from Caco-2 cells exposed to 10&#160;&#181;M phenethylamine; (A) cumulative peak area of phenylacetic acid in medium collected from the receiver compartment (=&#8201;basolateral compartment in A-B and apical compartment in B-A studies) after 0, 15, 30 and 60&#160;min of exposure; (B) phenylacetic acid in medium collected from the donor compartment (=&#8201;apical compartment in A-B and basolateral compartment in B-A studies) after 60&#160;min of exposure; data are presented as average peak area of m/z 137.046 from two different wells</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="MO10" orientation="portrait" xlink:href="204_2025_3992_Fig10_HTML.jpg"/></fig></sec></app></app-group><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="funding-information"><title>Funding</title><p>This research was funded by the Dutch Ministry of Agriculture, Nature and Food Quality.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Conflict of Interest</title><p id="Par38">The authors declare that there are no conflicts of interest.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><mixed-citation publication-type="other">Alhayek S, Preuss CV (2024) Beta 1 Receptors StatPearls. StatPearls Publishing. Copyright &#169; 2024, StatPearls Publishing LLC., Treasure Island (FL)<pub-id pub-id-type="pmid">30422499</pub-id></mixed-citation></ref><ref id="CR2"><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alsenz</surname><given-names>J</given-names></name><name name-style="western"><surname>Haenel</surname><given-names>E</given-names></name></person-group><article-title>Development of a 7-day, 96-well Caco-2 permeability assay with high-throughput direct UV compound analysis</article-title><source>Pharm Res</source><year>2003</year><volume>20</volume><issue>12</issue><fpage>1961</fpage><lpage>1969</lpage><pub-id pub-id-type="doi">10.1023/b:pham.0000008043.71001.43</pub-id><pub-id pub-id-type="pmid">14725360</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Alsenz J, Haenel E (2003) Development of a 7-day, 96-well Caco-2 permeability assay with high-throughput direct UV compound analysis. Pharm Res 20(12):1961&#8211;1969. 10.1023/b:pham.0000008043.71001.43<pub-id pub-id-type="pmid">14725360</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1023/b:pham.0000008043.71001.43</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Artursson</surname><given-names>P</given-names></name><name name-style="western"><surname>Karlsson</surname><given-names>J</given-names></name></person-group><article-title>Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells</article-title><source>Biochem Biophys Res Commun</source><year>1991</year><volume>175</volume><issue>3</issue><fpage>880</fpage><lpage>885</lpage><pub-id pub-id-type="doi">10.1016/0006-291X(91)91647-U</pub-id><pub-id pub-id-type="pmid">1673839</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Artursson P, Karlsson J (1991) Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun 175(3):880&#8211;885. 10.1016/0006-291X(91)91647-U<pub-id pub-id-type="pmid">1673839</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0006-291x(91)91647-u</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Avula</surname><given-names>B</given-names></name><name name-style="western"><surname>Bae</surname><given-names>J-Y</given-names></name><name name-style="western"><surname>Chittiboyina</surname><given-names>AG</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y-H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name><name name-style="western"><surname>Khan</surname><given-names>IA</given-names></name></person-group><article-title>Liquid chromatography-quadrupole time of flight mass spectrometric method for targeted analysis of 111 nitrogen-based compounds in weight loss and ergogenic supplements</article-title><source>J Pharm Biomed Anal</source><year>2019</year><volume>174</volume><fpage>305</fpage><lpage>323</lpage><pub-id pub-id-type="doi">10.1016/j.jpba.2019.05.066</pub-id><pub-id pub-id-type="pmid">31195319</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Avula B, Bae J-Y, Chittiboyina AG, Wang Y-H, Wang M, Khan IA (2019) Liquid chromatography-quadrupole time of flight mass spectrometric method for targeted analysis of 111 nitrogen-based compounds in weight loss and ergogenic supplements. J Pharm Biomed Anal 174:305&#8211;323. 10.1016/j.jpba.2019.05.066<pub-id pub-id-type="pmid">31195319</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jpba.2019.05.066</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Balsa</surname><given-names>MD</given-names></name><name name-style="western"><surname>G&#243;mez</surname><given-names>N</given-names></name><name name-style="western"><surname>Unzeta</surname><given-names>M</given-names></name></person-group><article-title>Characterization of monoamine oxidase activity present in human granulocytes and lymphocytes</article-title><source>Biochimica Et Biophysica Acta (BBA) - General Subjects</source><year>1989</year><volume>992</volume><issue>2</issue><fpage>140</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1016/0304-4165(89)90002-0</pub-id><pub-id pub-id-type="pmid">2503040</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Balsa MD, G&#243;mez N, Unzeta M (1989) Characterization of monoamine oxidase activity present in human granulocytes and lymphocytes. Biochimica Et Biophysica Acta (BBA) - General Subjects 992(2):140&#8211;144<pub-id pub-id-type="pmid">2503040</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0304-4165(89)90002-0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Biesterbos</surname><given-names>JWH</given-names></name><name name-style="western"><surname>Sijm</surname><given-names>D</given-names></name><name name-style="western"><surname>van Dam</surname><given-names>R</given-names></name><name name-style="western"><surname>Mol</surname><given-names>HGJ</given-names></name></person-group><article-title>A health risk for consumers: the presence of adulterated food supplements in the Netherlands</article-title><source>Food Addit Contam Part A Chem Anal Control Expo Risk Assess</source><year>2019</year><volume>36</volume><issue>9</issue><fpage>1273</fpage><lpage>1288</lpage><pub-id pub-id-type="doi">10.1080/19440049.2019.1633020</pub-id><pub-id pub-id-type="pmid">31294678</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Biesterbos JWH, Sijm D, van Dam R, Mol HGJ (2019) A health risk for consumers: the presence of adulterated food supplements in the Netherlands. Food Addit Contam Part A Chem Anal Control Expo Risk Assess 36(9):1273&#8211;1288. 10.1080/19440049.2019.1633020<pub-id pub-id-type="pmid">31294678</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/19440049.2019.1633020</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bovee</surname><given-names>TF</given-names></name><name name-style="western"><surname>Mol</surname><given-names>HG</given-names></name><name name-style="western"><surname>Bienenmann-Ploum</surname><given-names>ME</given-names></name><etal/></person-group><article-title>Dietary supplement for energy and reduced appetite containing the &#946;-agonist isopropyloctopamine leads to heart problems and hospitalisations</article-title><source>Food Addit Contam Part A Chem Anal Control Expo Risk Assess</source><year>2016</year><volume>33</volume><issue>5</issue><fpage>749</fpage><lpage>759</lpage><pub-id pub-id-type="doi">10.1080/19440049.2016.1167965</pub-id><pub-id pub-id-type="pmid">27092588</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Bovee TF, Mol HG, Bienenmann-Ploum ME et al (2016) Dietary supplement for energy and reduced appetite containing the &#946;-agonist isopropyloctopamine leads to heart problems and hospitalisations. Food Addit Contam Part A Chem Anal Control Expo Risk Assess 33(5):749&#8211;759. 10.1080/19440049.2016.1167965<pub-id pub-id-type="pmid">27092588</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/19440049.2016.1167965</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Broadley</surname><given-names>KJ</given-names></name></person-group><article-title>The vascular effects of trace amines and amphetamines</article-title><source>Pharmacol Ther</source><year>2010</year><volume>125</volume><issue>3</issue><fpage>363</fpage><lpage>375</lpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2009.11.005</pub-id><pub-id pub-id-type="pmid">19948186</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Broadley KJ (2010) The vascular effects of trace amines and amphetamines. Pharmacol Ther 125(3):363&#8211;375. 10.1016/j.pharmthera.2009.11.005<pub-id pub-id-type="pmid">19948186</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pharmthera.2009.11.005</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brown</surname><given-names>RP</given-names></name><name name-style="western"><surname>Delp</surname><given-names>MD</given-names></name><name name-style="western"><surname>Lindstedt</surname><given-names>SL</given-names></name><name name-style="western"><surname>Rhomberg</surname><given-names>LR</given-names></name><name name-style="western"><surname>Beliles</surname><given-names>RP</given-names></name></person-group><article-title>Physiological parameter values for physiologically based pharmacokinetic models</article-title><source>Toxicol Ind Health</source><year>1997</year><volume>13</volume><issue>4</issue><fpage>407</fpage><lpage>484</lpage><pub-id pub-id-type="doi">10.1177/074823379701300401</pub-id><pub-id pub-id-type="pmid">9249929</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Brown RP, Delp MD, Lindstedt SL, Rhomberg LR, Beliles RP (1997) Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health 13(4):407&#8211;484. 10.1177/074823379701300401<pub-id pub-id-type="pmid">9249929</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/074823379701300401</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>PA</given-names></name><name name-style="western"><surname>Zeijlon</surname><given-names>R</given-names></name><name name-style="western"><surname>Nardin</surname><given-names>R</given-names></name><name name-style="western"><surname>Keizers</surname><given-names>PHJ</given-names></name><name name-style="western"><surname>Venhuis</surname><given-names>B</given-names></name></person-group><article-title>Hemorrhagic stroke probably caused by exercise combined with a sports supplement containing &#946;-Methylphenyl-ethylamine (BMPEA): A Case Report</article-title><source>Ann Intern Med</source><year>2015</year><volume>162</volume><issue>12</issue><fpage>879</fpage><lpage>880</lpage><pub-id pub-id-type="doi">10.7326/L15-0106</pub-id><pub-id pub-id-type="pmid">26075771</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Cohen PA, Zeijlon R, Nardin R, Keizers PHJ, Venhuis B (2015a) Hemorrhagic stroke probably caused by exercise combined with a sports supplement containing &#946;-Methylphenyl-ethylamine (BMPEA): A Case Report. Ann Intern Med 162(12):879&#8211;880. 10.7326/L15-0106<pub-id pub-id-type="pmid">26075771</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/L15-5101</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>PA</given-names></name><name name-style="western"><surname>Zeijlon</surname><given-names>R</given-names></name><name name-style="western"><surname>Nardin</surname><given-names>R</given-names></name><name name-style="western"><surname>Keizers</surname><given-names>PHJ</given-names></name><name name-style="western"><surname>Venhuis</surname><given-names>B</given-names></name></person-group><article-title>Hemorrhagic stroke probably caused by exercise combined with a sports supplement containing &#946;-Methylphenyl-ethylamine (BMPEA): A Case Report</article-title><source>Ann Int Med</source><year>2015</year><volume>162</volume><fpage>879</fpage><lpage>880</lpage><pub-id pub-id-type="doi">10.7326/L15-0106</pub-id><pub-id pub-id-type="pmid">26075771</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Cohen PA, Zeijlon R, Nardin R, Keizers PHJ, Venhuis B (2015b) Hemorrhagic stroke probably caused by exercise combined with a sports supplement containing &#946;-Methylphenyl-ethylamine (BMPEA): A Case Report. Ann Int Med 162:879&#8211;880<pub-id pub-id-type="pmid">26075771</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/L15-5101</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>PA</given-names></name><name name-style="western"><surname>Travis</surname><given-names>JC</given-names></name><name name-style="western"><surname>Vanhee</surname><given-names>C</given-names></name><name name-style="western"><surname>Ohana</surname><given-names>D</given-names></name><name name-style="western"><surname>Venhuis</surname><given-names>BJ</given-names></name></person-group><article-title>Nine prohibited stimulants found in sports and weight loss supplements: deterenol, phenpromethamine (Vonedrine), oxilofrine, octodrine, beta-methylphenylethylamine (BMPEA), 1,3-dimethylamylamine (1,3-DMAA), 1,4-dimethylamylamine (1,4-DMAA), 1,3-dimethylbutylamine (1,3-DMBA) and higenamine</article-title><source>Clin Toxicol (Phila)</source><year>2021</year><volume>59</volume><issue>11</issue><fpage>975</fpage><lpage>981</lpage><pub-id pub-id-type="doi">10.1080/15563650.2021.1894333</pub-id><pub-id pub-id-type="pmid">33755516</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Cohen PA, Travis JC, Vanhee C, Ohana D, Venhuis BJ (2021) Nine prohibited stimulants found in sports and weight loss supplements: deterenol, phenpromethamine (Vonedrine), oxilofrine, octodrine, beta-methylphenylethylamine (BMPEA), 1,3-dimethylamylamine (1,3-DMAA), 1,4-dimethylamylamine (1,4-DMAA), 1,3-dimethylbutylamine (1,3-DMBA) and higenamine. Clin Toxicol (Phila) 59(11):975&#8211;981. 10.1080/15563650.2021.1894333<pub-id pub-id-type="pmid">33755516</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/15563650.2021.1894333</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Czepielewska</surname><given-names>E</given-names></name><name name-style="western"><surname>Makarewicz-Wujec</surname><given-names>M</given-names></name><name name-style="western"><surname>R&#243;&#380;ewski</surname><given-names>F</given-names></name><name name-style="western"><surname>Wojtasik</surname><given-names>E</given-names></name><name name-style="western"><surname>Koz&#322;owska-Wojciechowska</surname><given-names>M</given-names></name></person-group><article-title>Drug adulteration of food supplements: A threat to public health in the European Union?</article-title><source>Regul Toxicol Pharmacol</source><year>2018</year><volume>97</volume><fpage>98</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1016/j.yrtph.2018.06.014</pub-id><pub-id pub-id-type="pmid">29932980</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Czepielewska E, Makarewicz-Wujec M, R&#243;&#380;ewski F, Wojtasik E, Koz&#322;owska-Wojciechowska M (2018) Drug adulteration of food supplements: A threat to public health in the European Union? Regul Toxicol Pharmacol 97:98&#8211;102. 10.1016/j.yrtph.2018.06.014<pub-id pub-id-type="pmid">29932980</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.yrtph.2018.06.014</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Jonge</surname><given-names>MLL</given-names></name><name name-style="western"><surname>Kieviet</surname><given-names>LC</given-names></name><name name-style="western"><surname>Sierts</surname><given-names>M</given-names></name><name name-style="western"><surname>Egberink</surname><given-names>LB</given-names></name><name name-style="western"><surname>van der Heyden</surname><given-names>MAG</given-names></name></person-group><article-title>Review of case reports on adverse events related to pre-workout supplements containing synephrine</article-title><source>Cardiovasc Toxicol</source><year>2023</year><volume>23</volume><issue>1</issue><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1007/s12012-022-09777-z</pub-id><pub-id pub-id-type="pmid">36639595</pub-id><pub-id pub-id-type="pmcid">PMC9859859</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">de Jonge MLL, Kieviet LC, Sierts M, Egberink LB, van der Heyden MAG (2023) Review of case reports on adverse events related to pre-workout supplements containing synephrine. Cardiovasc Toxicol 23(1):1&#8211;9. 10.1007/s12012-022-09777-z<pub-id pub-id-type="pmid">36639595</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12012-022-09777-z</pub-id><pub-id pub-id-type="pmcid">PMC9859859</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duiven</surname><given-names>E</given-names></name><name name-style="western"><surname>van Loon</surname><given-names>LJC</given-names></name><name name-style="western"><surname>Spruijt</surname><given-names>L</given-names></name><name name-style="western"><surname>Koert</surname><given-names>W</given-names></name><name name-style="western"><surname>de Hon</surname><given-names>OM</given-names></name></person-group><article-title>Undeclared doping substances are highly prevalent in commercial sports nutrition supplements</article-title><source>J Sports Sci Med</source><year>2021</year><volume>20</volume><issue>2</issue><fpage>328</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.52082/jssm.2021.328</pub-id><pub-id pub-id-type="pmid">34211326</pub-id><pub-id pub-id-type="pmcid">PMC8219275</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Duiven E, van Loon LJC, Spruijt L, Koert W, de Hon OM (2021) Undeclared doping substances are highly prevalent in commercial sports nutrition supplements. J Sports Sci Med 20(2):328&#8211;338. 10.52082/jssm.2021.328<pub-id pub-id-type="pmid">34211326</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.52082/jssm.2021.328</pub-id><pub-id pub-id-type="pmcid">PMC8219275</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Evans</surname><given-names>MV</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>ME</given-names></name></person-group><article-title>Sensitivity Analysis of a Physiological Model for 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD): assessing the impact of specific model parameters on sequestration in liver and fat in the rat</article-title><source>Toxicol Sci</source><year>2000</year><volume>54</volume><issue>1</issue><fpage>71</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1093/toxsci/54.1.71</pub-id><pub-id pub-id-type="pmid">10746933</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Evans MV, Andersen ME (2000) Sensitivity Analysis of a Physiological Model for 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD): assessing the impact of specific model parameters on sequestration in liver and fat in the rat. Toxicol Sci 54(1):71&#8211;80. 10.1093/toxsci/54.1.71<pub-id pub-id-type="pmid">10746933</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/toxsci/54.1.71</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Faraj</surname><given-names>BA</given-names></name><name name-style="western"><surname>Fulenwider</surname><given-names>JT</given-names></name><name name-style="western"><surname>Rypins</surname><given-names>EB</given-names></name><etal/></person-group><article-title>Tyramine kinetics and metabolism in cirrhosis</article-title><source>J Clin Invest</source><year>1979</year><volume>64</volume><issue>2</issue><fpage>413</fpage><lpage>420</lpage><pub-id pub-id-type="doi">10.1172/jci109477</pub-id><pub-id pub-id-type="pmid">457860</pub-id><pub-id pub-id-type="pmcid">PMC372134</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Faraj BA, Fulenwider JT, Rypins EB et al (1979) Tyramine kinetics and metabolism in cirrhosis. J Clin Invest 64(2):413&#8211;420. 10.1172/jci109477<pub-id pub-id-type="pmid">457860</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI109477</pub-id><pub-id pub-id-type="pmcid">PMC372134</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feng</surname><given-names>S</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>J</given-names></name><name name-style="western"><surname>Hu</surname><given-names>P</given-names></name><etal/></person-group><article-title>A phase I study on pharmacokinetics and pharmacodynamics of higenamine in healthy Chinese subjects</article-title><source>Acta Pharmacol Sin</source><year>2012</year><volume>33</volume><issue>11</issue><fpage>1353</fpage><lpage>1358</lpage><pub-id pub-id-type="doi">10.1038/aps.2012.114</pub-id><pub-id pub-id-type="pmid">23085737</pub-id><pub-id pub-id-type="pmcid">PMC4011356</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Feng S, Jiang J, Hu P et al (2012) A phase I study on pharmacokinetics and pharmacodynamics of higenamine in healthy Chinese subjects. Acta Pharmacol Sin 33(11):1353&#8211;1358. 10.1038/aps.2012.114<pub-id pub-id-type="pmid">23085737</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/aps.2012.114</pub-id><pub-id pub-id-type="pmcid">PMC4011356</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fischer</surname><given-names>I</given-names></name><name name-style="western"><surname>Milton</surname><given-names>C</given-names></name><name name-style="western"><surname>Wallace</surname><given-names>H</given-names></name></person-group><article-title>Toxicity testing is evolving!</article-title><source>Toxicol Res</source><year>2020</year><volume>9</volume><issue>2</issue><fpage>67</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1093/toxres/tfaa011</pub-id><pub-id pub-id-type="pmcid">PMC7233318</pub-id><pub-id pub-id-type="pmid">32440338</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Fischer I, Milton C, Wallace H (2020) Toxicity testing is evolving! Toxicol Res 9(2):67&#8211;80. 10.1093/toxres/tfaa011<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/toxres/tfaa011</pub-id><pub-id pub-id-type="pmcid">PMC7233318</pub-id><pub-id pub-id-type="pmid">32440338</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Galkin</surname><given-names>A</given-names></name><name name-style="western"><surname>Pakkanen</surname><given-names>J</given-names></name><name name-style="western"><surname>Vuorela</surname><given-names>P</given-names></name></person-group><article-title>Development of an automated 7-day 96-well Caco-2 cell culture model</article-title><source>Pharmazie</source><year>2008</year><volume>63</volume><issue>6</issue><fpage>464</fpage><lpage>469</lpage><pub-id pub-id-type="pmid">18604991</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Galkin A, Pakkanen J, Vuorela P (2008) Development of an automated 7-day 96-well Caco-2 cell culture model. Pharmazie 63(6):464&#8211;469<pub-id pub-id-type="pmid">18604991</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gertz</surname><given-names>M</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>A</given-names></name><name name-style="western"><surname>Houston</surname><given-names>JB</given-names></name><name name-style="western"><surname>Galetin</surname><given-names>A</given-names></name></person-group><article-title>Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data</article-title><source>Drug Metab Dispos</source><year>2010</year><volume>38</volume><issue>7</issue><fpage>1147</fpage><lpage>1158</lpage><pub-id pub-id-type="doi">10.1124/dmd.110.032649</pub-id><pub-id pub-id-type="pmid">20368326</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Gertz M, Harrison A, Houston JB, Galetin A (2010) Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data. Drug Metab Dispos 38(7):1147&#8211;1158. 10.1124/dmd.110.032649<pub-id pub-id-type="pmid">20368326</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.110.032649</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Graham</surname><given-names>RM</given-names></name></person-group><article-title>Adrenergic receptors: structure and function</article-title><source>Cleve Clin J Med</source><year>1990</year><volume>57</volume><issue>5</issue><fpage>481</fpage><lpage>491</lpage><pub-id pub-id-type="doi">10.3949/ccjm.57.5.481</pub-id><pub-id pub-id-type="pmid">2164898</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Graham RM (1990) Adrenergic receptors: structure and function. Cleve Clin J Med 57(5):481&#8211;491. 10.3949/ccjm.57.5.481<pub-id pub-id-type="pmid">2164898</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3949/ccjm.57.5.481</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grandoni</surname><given-names>S</given-names></name><name name-style="western"><surname>Cesari</surname><given-names>N</given-names></name><name name-style="western"><surname>Brogin</surname><given-names>G</given-names></name><name name-style="western"><surname>Puccini</surname><given-names>P</given-names></name><name name-style="western"><surname>Magni</surname><given-names>P</given-names></name></person-group><article-title>Building in-house PBPK modelling tools for oral drug administration from literature information</article-title><source>Admet Dmpk</source><year>2019</year><volume>7</volume><issue>1</issue><fpage>4</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.5599/admet.638</pub-id><pub-id pub-id-type="pmid">35350741</pub-id><pub-id pub-id-type="pmcid">PMC8957249</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Grandoni S, Cesari N, Brogin G, Puccini P, Magni P (2019) Building in-house PBPK modelling tools for oral drug administration from literature information. Admet Dmpk 7(1):4&#8211;21. 10.5599/admet.638<pub-id pub-id-type="pmid">35350741</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5599/admet.638</pub-id><pub-id pub-id-type="pmcid">PMC8957249</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hallifax</surname><given-names>D</given-names></name><name name-style="western"><surname>Houston</surname><given-names>JB</given-names></name></person-group><article-title>Binding of drugs to hepatic microsomes: comment and assessment of current prediction methodology with recommendation for improvement</article-title><source>Drug Metab Dispos</source><year>2006</year><volume>34</volume><issue>4</issue><fpage>724</fpage><lpage>726</lpage><pub-id pub-id-type="doi">10.1124/dmd.105.007658</pub-id><pub-id pub-id-type="pmid">16552024</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Hallifax D, Houston JB (2006) Binding of drugs to hepatic microsomes: comment and assessment of current prediction methodology with recommendation for improvement. Drug Metab Dispos 34(4):724&#8211;726<pub-id pub-id-type="pmid">16552024</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.105.007658</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harris</surname><given-names>BF</given-names></name><name name-style="western"><surname>Winn</surname><given-names>C</given-names></name><name name-style="western"><surname>Ableman</surname><given-names>TB</given-names></name></person-group><article-title>Hemorrhagic stroke in a young healthy male following use of pre-workout supplement animal rage XL</article-title><source>Mil Med</source><year>2017</year><volume>182</volume><issue>9&#8211;10</issue><fpage>e2030</fpage><lpage>e2033</lpage><pub-id pub-id-type="doi">10.7205/milmed-d-17-00013</pub-id><pub-id pub-id-type="pmid">28885973</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Harris BF, Winn C, Ableman TB (2017) Hemorrhagic stroke in a young healthy male following use of pre-workout supplement animal rage XL. Mil Med 182(9&#8211;10):e2030&#8211;e2033. 10.7205/milmed-d-17-00013<pub-id pub-id-type="pmid">28885973</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7205/MILMED-D-17-00013</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hilgendorf</surname><given-names>C</given-names></name><name name-style="western"><surname>Spahn-Langguth</surname><given-names>H</given-names></name><name name-style="western"><surname>Reg&#229;rdh</surname><given-names>CG</given-names></name><name name-style="western"><surname>Lipka</surname><given-names>E</given-names></name><name name-style="western"><surname>Amidon</surname><given-names>GL</given-names></name><name name-style="western"><surname>Langguth</surname><given-names>P</given-names></name></person-group><article-title>Caco-2 versus Caco-2/HT29-MTX co-cultured cell lines: permeabilities via diffusion, inside- and outside-directed carrier-mediated transport</article-title><source>J Pharm Sci</source><year>2000</year><volume>89</volume><issue>1</issue><fpage>63</fpage><lpage>75</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/(SICI)1520-6017(200001)89:1&amp;#x0003c;63::AID-JPS7&amp;#x0003e;3.0.CO;2-6</pub-id><pub-id pub-id-type="pmid">10664539</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Hilgendorf C, Spahn-Langguth H, Reg&#229;rdh CG, Lipka E, Amidon GL, Langguth P (2000) Caco-2 versus Caco-2/HT29-MTX co-cultured cell lines: permeabilities via diffusion, inside- and outside-directed carrier-mediated transport. J Pharm Sci 89(1):63&#8211;75. 10.1002/(SICI)1520-6017(200001)89:1%3c63::AID-JPS7%3e3.0.CO;2-6<pub-id pub-id-type="pmid">10664539</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/(SICI)1520-6017(200001)89:1&lt;63::AID-JPS7&gt;3.0.CO;2-6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hiroi</surname><given-names>T</given-names></name><name name-style="western"><surname>Imaoka</surname><given-names>S</given-names></name><name name-style="western"><surname>Funae</surname><given-names>Y</given-names></name></person-group><article-title>Dopamine Formation from Tyramine by CYP2D6</article-title><source>Biochem Biophys Res Commun</source><year>1998</year><volume>249</volume><issue>3</issue><fpage>838</fpage><lpage>843</lpage><pub-id pub-id-type="doi">10.1006/bbrc.1998.9232</pub-id><pub-id pub-id-type="pmid">9731223</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Hiroi T, Imaoka S, Funae Y (1998) Dopamine Formation from Tyramine by CYP2D6. Biochem Biophys Res Commun 249(3):838&#8211;843. 10.1006/bbrc.1998.9232<pub-id pub-id-type="pmid">9731223</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1006/bbrc.1998.9232</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Houston</surname><given-names>JB</given-names></name><name name-style="western"><surname>Galetin</surname><given-names>A</given-names></name></person-group><article-title>Methods for predicting in vivo pharmacokinetics using data from in vitro assays</article-title><source>Curr Drug Metab</source><year>2008</year><volume>9</volume><issue>9</issue><fpage>940</fpage><lpage>951</lpage><pub-id pub-id-type="doi">10.2174/138920008786485164</pub-id><pub-id pub-id-type="pmid">18991591</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Houston JB, Galetin A (2008) Methods for predicting in vivo pharmacokinetics using data from in vitro assays. Curr Drug Metab 9(9):940&#8211;951. 10.2174/138920008786485164<pub-id pub-id-type="pmid">18991591</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/138920008786485164</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hubatsch</surname><given-names>I</given-names></name><name name-style="western"><surname>Ragnarsson</surname><given-names>EG</given-names></name><name name-style="western"><surname>Artursson</surname><given-names>P</given-names></name></person-group><article-title>Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers</article-title><source>Nat Protoc</source><year>2007</year><volume>2</volume><issue>9</issue><fpage>2111</fpage><lpage>2119</lpage><pub-id pub-id-type="doi">10.1038/nprot.2007.303</pub-id><pub-id pub-id-type="pmid">17853866</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Hubatsch I, Ragnarsson EG, Artursson P (2007) Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers. Nat Protoc 2(9):2111&#8211;2119. 10.1038/nprot.2007.303<pub-id pub-id-type="pmid">17853866</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nprot.2007.303</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hudzik</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Patel</surname><given-names>M</given-names></name><name name-style="western"><surname>Brown</surname><given-names>A</given-names></name><name name-style="western"><surname>Thomas Hudzik</surname><given-names>CJ</given-names></name><collab>Y W O R D S higenamine KE</collab></person-group><article-title>M I N I-R E V I E W &#946; 2-Adrenoceptor agonist activity of higenamine</article-title><source>Drug Test Anal</source><year>2020</year><volume>13</volume><fpage>261</fpage><lpage>267</lpage><pub-id pub-id-type="doi">10.1002/dta.2992</pub-id><pub-id pub-id-type="pmcid">PMC7898339</pub-id><pub-id pub-id-type="pmid">33369180</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Hudzik TJ, Patel M, Brown A, Thomas Hudzik CJ, Y W O R D S higenamine KE (2020) M I N I-R E V I E W &#946; 2-Adrenoceptor agonist activity of higenamine. Drug Test Anal 13:261&#8211;267<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/dta.2992</pub-id><pub-id pub-id-type="pmcid">PMC7898339</pub-id><pub-id pub-id-type="pmid">33369180</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Incecayir</surname><given-names>T</given-names></name><name name-style="western"><surname>Tsume</surname><given-names>Y</given-names></name><name name-style="western"><surname>Amidon</surname><given-names>GL</given-names></name></person-group><article-title>Comparison of the permeability of metoprolol and labetalol in rat, mouse, and Caco-2 cells: use as a reference standard for BCS classification</article-title><source>Mol Pharm</source><year>2013</year><volume>10</volume><issue>3</issue><fpage>958</fpage><lpage>966</lpage><pub-id pub-id-type="doi">10.1021/mp300410n</pub-id><pub-id pub-id-type="pmid">23327720</pub-id><pub-id pub-id-type="pmcid">PMC3605724</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Incecayir T, Tsume Y, Amidon GL (2013) Comparison of the permeability of metoprolol and labetalol in rat, mouse, and Caco-2 cells: use as a reference standard for BCS classification. Mol Pharm 10(3):958&#8211;966. 10.1021/mp300410n<pub-id pub-id-type="pmid">23327720</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/mp300410n</pub-id><pub-id pub-id-type="pmcid">PMC3605724</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Irvine</surname><given-names>JD</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>L</given-names></name><name name-style="western"><surname>Lockhart</surname><given-names>K</given-names></name><etal/></person-group><article-title>MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening</article-title><source>J Pharm Sci</source><year>1999</year><volume>88</volume><issue>1</issue><fpage>28</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1021/js9803205</pub-id><pub-id pub-id-type="pmid">9874698</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Irvine JD, Takahashi L, Lockhart K et al (1999) MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci 88(1):28&#8211;33. 10.1021/js9803205<pub-id pub-id-type="pmid">9874698</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/js9803205</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iwasa</surname><given-names>T</given-names></name><name name-style="western"><surname>Sano</surname><given-names>H</given-names></name><name name-style="western"><surname>Sugiura</surname><given-names>A</given-names></name><etal/></person-group><article-title>An in vitro interethnic comparison of monoamine oxidase activities between Japanese and Caucasian livers using rizatriptan, a serotonin receptor 1B/1D agonist, as a model drug</article-title><source>Br J Clin Pharmacol</source><year>2003</year><volume>56</volume><issue>5</issue><fpage>537</fpage><lpage>544</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2125.2003.01922.x</pub-id><pub-id pub-id-type="pmid">14651728</pub-id><pub-id pub-id-type="pmcid">PMC1884399</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Iwasa T, Sano H, Sugiura A et al (2003) An in vitro interethnic comparison of monoamine oxidase activities between Japanese and Caucasian livers using rizatriptan, a serotonin receptor 1B/1D agonist, as a model drug. Br J Clin Pharmacol 56(5):537&#8211;544. 10.1046/j.1365-2125.2003.01922.x<pub-id pub-id-type="pmid">14651728</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1365-2125.2003.01922.x</pub-id><pub-id pub-id-type="pmcid">PMC1884399</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>HM</given-names></name><name name-style="western"><surname>Rowland-Yeo</surname><given-names>K</given-names></name></person-group><article-title>Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development</article-title><source>CPT Pharmacometrics Syst Pharmacol</source><year>2013</year><volume>2</volume><issue>8</issue><fpage>63</fpage><pub-id pub-id-type="doi">10.1038/psp.2013.41</pub-id><pub-id pub-id-type="pmcid">PMC3828005</pub-id><pub-id pub-id-type="pmid">23945604</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Jones HM, Rowland-Yeo K (2013) Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development. CPT Pharmacometrics Syst Pharmacol 2(8):63. 10.1038/psp.2013.41<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/psp.2013.41</pub-id><pub-id pub-id-type="pmcid">PMC3828005</pub-id><pub-id pub-id-type="pmid">23945604</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joyner</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Casey</surname><given-names>DP</given-names></name></person-group><article-title>Regulation of increased blood flow (hyperemia) to muscles during exercise: a hierarchy of competing physiological needs</article-title><source>Physiol Rev</source><year>2015</year><volume>95</volume><issue>2</issue><fpage>549</fpage><lpage>601</lpage><pub-id pub-id-type="doi">10.1152/physrev.00035.2013</pub-id><pub-id pub-id-type="pmid">25834232</pub-id><pub-id pub-id-type="pmcid">PMC4551211</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Joyner MJ, Casey DP (2015) Regulation of increased blood flow (hyperemia) to muscles during exercise: a hierarchy of competing physiological needs. Physiol Rev 95(2):549&#8211;601. 10.1152/physrev.00035.2013<pub-id pub-id-type="pmid">25834232</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/physrev.00035.2013</pub-id><pub-id pub-id-type="pmcid">PMC4551211</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kerns</surname><given-names>EH</given-names></name><name name-style="western"><surname>Di</surname><given-names>L</given-names></name><name name-style="western"><surname>Petusky</surname><given-names>S</given-names></name><name name-style="western"><surname>Farris</surname><given-names>M</given-names></name><name name-style="western"><surname>Ley</surname><given-names>R</given-names></name><name name-style="western"><surname>Jupp</surname><given-names>P</given-names></name></person-group><article-title>Combined application of parallel artificial membrane permeability assay and caco-2 permeability assays in drug discovery</article-title><source>J Pharm Sci</source><year>2004</year><volume>93</volume><issue>6</issue><fpage>1440</fpage><lpage>1453</lpage><pub-id pub-id-type="doi">10.1002/jps.20075</pub-id><pub-id pub-id-type="pmid">15124203</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Kerns EH, Di L, Petusky S, Farris M, Ley R, Jupp P (2004) Combined application of parallel artificial membrane permeability assay and caco-2 permeability assays in drug discovery. J Pharm Sci 93(6):1440&#8211;1453. 10.1002/jps.20075<pub-id pub-id-type="pmid">15124203</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jps.20075</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koh</surname><given-names>AHW</given-names></name><name name-style="western"><surname>Chess-Williams</surname><given-names>R</given-names></name><name name-style="western"><surname>Lohning</surname><given-names>AE</given-names></name></person-group><article-title>HPLC-UV-QDa analysis of Citrus aurantium-labelled pre-workout supplements suggest only a minority contain the plant extract</article-title><source>J Pharm Biomed Anal</source><year>2021</year><volume>193</volume><fpage>113746</fpage><pub-id pub-id-type="doi">10.1016/j.jpba.2020.113746</pub-id><pub-id pub-id-type="pmid">33190081</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Koh AHW, Chess-Williams R, Lohning AE (2021) HPLC-UV-QDa analysis of Citrus aurantium-labelled pre-workout supplements suggest only a minority contain the plant extract. J Pharm Biomed Anal 193:113746. 10.1016/j.jpba.2020.113746<pub-id pub-id-type="pmid">33190081</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jpba.2020.113746</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>JB</given-names></name><name name-style="western"><surname>Zgair</surname><given-names>A</given-names></name><name name-style="western"><surname>Taha</surname><given-names>DA</given-names></name><etal/></person-group><article-title>Quantitative analysis of lab-to-lab variability in Caco-2 permeability assays</article-title><source>Eur J Pharm Biopharm</source><year>2017</year><volume>114</volume><fpage>38</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2016.12.027</pub-id><pub-id pub-id-type="pmid">28088633</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Lee JB, Zgair A, Taha DA et al (2017) Quantitative analysis of lab-to-lab variability in Caco-2 permeability assays. Eur J Pharm Biopharm 114:38&#8211;42. 10.1016/j.ejpb.2016.12.027<pub-id pub-id-type="pmid">28088633</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejpb.2016.12.027</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lentz</surname><given-names>KA</given-names></name><name name-style="western"><surname>Hayashi</surname><given-names>J</given-names></name><name name-style="western"><surname>Lucisano</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Polli</surname><given-names>JE</given-names></name></person-group><article-title>Development of a more rapid, reduced serum culture system for Caco-2 monolayers and application to the biopharmaceutics classification system</article-title><source>Int J Pharm</source><year>2000</year><volume>200</volume><issue>1</issue><fpage>41</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1016/S0378-5173(00)00334-3</pub-id><pub-id pub-id-type="pmid">10845684</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Lentz KA, Hayashi J, Lucisano LJ, Polli JE (2000) Development of a more rapid, reduced serum culture system for Caco-2 monolayers and application to the biopharmaceutics classification system. Int J Pharm 200(1):41&#8211;51. 10.1016/S0378-5173(00)00334-3<pub-id pub-id-type="pmid">10845684</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0378-5173(00)00334-3</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>C</given-names></name><name name-style="western"><surname>Liu</surname><given-names>T</given-names></name><name name-style="western"><surname>Cui</surname><given-names>X</given-names></name><name name-style="western"><surname>Uss</surname><given-names>AS</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>KC</given-names></name></person-group><article-title>Development of in vitro pharmacokinetic screens using Caco-2, human hepatocyte, and Caco-2/human hepatocyte hybrid systems for the prediction of oral bioavailability in humans</article-title><source>J Biomol Screen</source><year>2007</year><volume>12</volume><issue>8</issue><fpage>1084</fpage><lpage>1091</lpage><pub-id pub-id-type="doi">10.1177/1087057107308892</pub-id><pub-id pub-id-type="pmid">17989424</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Li C, Liu T, Cui X, Uss AS, Cheng KC (2007) Development of in vitro pharmacokinetic screens using Caco-2, human hepatocyte, and Caco-2/human hepatocyte hybrid systems for the prediction of oral bioavailability in humans. J Biomol Screen 12(8):1084&#8211;1091. 10.1177/1087057107308892<pub-id pub-id-type="pmid">17989424</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1087057107308892</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lobell</surname><given-names>M</given-names></name><name name-style="western"><surname>Sivarajah</surname><given-names>V</given-names></name></person-group><article-title>In silico prediction of aqueous solubility, human plasma protein binding and volume of distribution of compounds from calculated pKa and AlogP98 values</article-title><source>Mol Diversity</source><year>2003</year><volume>7</volume><issue>1</issue><fpage>69</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1023/B:MODI.0000006562.93049.36</pub-id><pub-id pub-id-type="pmid">14768905</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Lobell M, Sivarajah V (2003) In silico prediction of aqueous solubility, human plasma protein binding and volume of distribution of compounds from calculated pKa and AlogP98 values. Mol Diversity 7(1):69&#8211;87. 10.1023/B:MODI.0000006562.93049.36<pub-id pub-id-type="doi" assigning-authority="pmc">10.1023/b:modi.0000006562.93049.36</pub-id><pub-id pub-id-type="pmid">14768905</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Louisse</surname><given-names>J</given-names></name><name name-style="western"><surname>Beekmann</surname><given-names>K</given-names></name><name name-style="western"><surname>Rietjens</surname><given-names>IM</given-names></name></person-group><article-title>Use of physiologically based kinetic modeling-based reverse dosimetry to predict in vivo toxicity from in vitro data</article-title><source>Chem Res Toxicol</source><year>2017</year><volume>30</volume><issue>1</issue><fpage>114</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.1021/acs.chemrestox.6b00302</pub-id><pub-id pub-id-type="pmid">27768849</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Louisse J, Beekmann K, Rietjens IM (2017) Use of physiologically based kinetic modeling-based reverse dosimetry to predict in vivo toxicity from in vitro data. Chem Res Toxicol 30(1):114&#8211;125. 10.1021/acs.chemrestox.6b00302<pub-id pub-id-type="pmid">27768849</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.chemrestox.6b00302</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Najjar</surname><given-names>A</given-names></name><name name-style="western"><surname>Punt</surname><given-names>A</given-names></name><name name-style="western"><surname>Wambaugh</surname><given-names>J</given-names></name><etal/></person-group><article-title>Towards best use and regulatory acceptance of generic physiologically based kinetic (PBK) models for in vitro-to-in vivo extrapolation (IVIVE) in chemical risk assessment</article-title><source>Arch Toxicol</source><year>2022</year><volume>96</volume><issue>12</issue><fpage>3407</fpage><lpage>3419</lpage><pub-id pub-id-type="doi">10.1007/s00204-022-03356-5</pub-id><pub-id pub-id-type="pmid">36063173</pub-id><pub-id pub-id-type="pmcid">PMC9584981</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Najjar A, Punt A, Wambaugh J et al (2022) Towards best use and regulatory acceptance of generic physiologically based kinetic (PBK) models for in vitro-to-in vivo extrapolation (IVIVE) in chemical risk assessment. Arch Toxicol 96(12):3407&#8211;3419. 10.1007/s00204-022-03356-5<pub-id pub-id-type="pmid">36063173</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00204-022-03356-5</pub-id><pub-id pub-id-type="pmcid">PMC9584981</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neuhoff</surname><given-names>S</given-names></name><name name-style="western"><surname>Ungell</surname><given-names>AL</given-names></name><name name-style="western"><surname>Zamora</surname><given-names>I</given-names></name><name name-style="western"><surname>Artursson</surname><given-names>P</given-names></name></person-group><article-title>pH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: implications for drug-drug interactions</article-title><source>Pharm Res</source><year>2003</year><volume>20</volume><issue>8</issue><fpage>1141</fpage><lpage>1148</lpage><pub-id pub-id-type="doi">10.1023/a:1025032511040</pub-id><pub-id pub-id-type="pmid">12948010</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Neuhoff S, Ungell AL, Zamora I, Artursson P (2003) pH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: implications for drug-drug interactions. Pharm Res 20(8):1141&#8211;1148. 10.1023/a:1025032511040<pub-id pub-id-type="pmid">12948010</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1023/a:1025032511040</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Obata</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kubota-Sakashita</surname><given-names>M</given-names></name><name name-style="western"><surname>Kasahara</surname><given-names>T</given-names></name><name name-style="western"><surname>Mizuno</surname><given-names>M</given-names></name><name name-style="western"><surname>Nemoto</surname><given-names>T</given-names></name><name name-style="western"><surname>Kato</surname><given-names>T</given-names></name></person-group><article-title>Phenethylamine is a substrate of monoamine oxidase B in the paraventricular thalamic nucleus</article-title><source>Sci Rep</source><year>2022</year><volume>12</volume><issue>1</issue><fpage>17</fpage><pub-id pub-id-type="doi">10.1038/s41598-021-03885-6</pub-id><pub-id pub-id-type="pmid">34996979</pub-id><pub-id pub-id-type="pmcid">PMC8742005</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Obata Y, Kubota-Sakashita M, Kasahara T, Mizuno M, Nemoto T, Kato T (2022) Phenethylamine is a substrate of monoamine oxidase B in the paraventricular thalamic nucleus. Sci Rep 12(1):17. 10.1038/s41598-021-03885-6<pub-id pub-id-type="pmid">34996979</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-021-03885-6</pub-id><pub-id pub-id-type="pmcid">PMC8742005</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oguchi</surname><given-names>K</given-names></name><name name-style="western"><surname>Kobayashi</surname><given-names>S</given-names></name><name name-style="western"><surname>Uesato</surname><given-names>T</given-names></name><name name-style="western"><surname>Kamijo</surname><given-names>K</given-names></name></person-group><article-title>Studies on beta-phenylethylamine deamination by human placental monoamine oxidase</article-title><source>Jpn J Pharmacol</source><year>1981</year><volume>31</volume><issue>1</issue><fpage>7</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1254/jjp.31.7</pub-id><pub-id pub-id-type="pmid">6788990</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Oguchi K, Kobayashi S, Uesato T, Kamijo K (1981) Studies on beta-phenylethylamine deamination by human placental monoamine oxidase. Jpn J Pharmacol 31(1):7&#8211;14. 10.1254/jjp.31.7<pub-id pub-id-type="pmid">6788990</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1254/jjp.31.7</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Otto</surname><given-names>S</given-names></name><name name-style="western"><surname>Vrolijk</surname><given-names>MF</given-names></name><name name-style="western"><surname>de Boer</surname><given-names>A</given-names></name></person-group><article-title>EU&#8217;s next generation risk assessment: hurdles and opportunities for new approach methodologies</article-title><source>J Consum Protect Food Safe</source><year>2023</year><volume>18</volume><issue>1</issue><fpage>3</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1007/s00003-022-01403-y</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Otto S, Vrolijk MF, de Boer A (2023) EU&#8217;s next generation risk assessment: hurdles and opportunities for new approach methodologies. J Consum Protect Food Safe 18(1):3&#8211;17. 10.1007/s00003-022-01403-y</mixed-citation></citation-alternatives></ref><ref id="CR48"><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palm</surname><given-names>K</given-names></name><name name-style="western"><surname>Luthman</surname><given-names>K</given-names></name><name name-style="western"><surname>Unge</surname><given-names>A-L</given-names></name><name name-style="western"><surname>Strandlund</surname><given-names>G</given-names></name><name name-style="western"><surname>Artursson</surname><given-names>P</given-names></name></person-group><article-title>Correlation of drug absorption with molecular surface properties</article-title><source>J Pharm Sci</source><year>1996</year><volume>85</volume><issue>1</issue><fpage>32</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1021/js950285r</pub-id><pub-id pub-id-type="pmid">8926580</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Palm K, Luthman K, Unge A-L, Strandlund G, Artursson P (1996) Correlation of drug absorption with molecular surface properties. J Pharm Sci 85(1):32&#8211;39. 10.1021/js950285r<pub-id pub-id-type="pmid">8926580</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/js950285r</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paul Friedman</surname><given-names>K</given-names></name><name name-style="western"><surname>Gagne</surname><given-names>M</given-names></name><name name-style="western"><surname>Loo</surname><given-names>L-H</given-names></name><etal/></person-group><article-title>Utility of in vitro bioactivity as a lower bound estimate of in vivo adverse effect levels and in risk-based prioritization</article-title><source>Toxicol Sci</source><year>2019</year><volume>173</volume><issue>1</issue><fpage>202</fpage><lpage>225</lpage><pub-id pub-id-type="doi">10.1093/toxsci/kfz201</pub-id><pub-id pub-id-type="pmcid">PMC7720780</pub-id><pub-id pub-id-type="pmid">31532525</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Paul Friedman K, Gagne M, Loo L-H et al (2019) Utility of in vitro bioactivity as a lower bound estimate of in vivo adverse effect levels and in risk-based prioritization. Toxicol Sci 173(1):202&#8211;225. 10.1093/toxsci/kfz201<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/toxsci/kfz201</pub-id><pub-id pub-id-type="pmcid">PMC7720780</pub-id><pub-id pub-id-type="pmid">31532525</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pawar</surname><given-names>RS</given-names></name><name name-style="western"><surname>Sagi</surname><given-names>S</given-names></name><name name-style="western"><surname>Leontyev</surname><given-names>D</given-names></name></person-group><article-title>Analysis of bitter orange dietary supplements for natural and synthetic phenethylamines by LC-MS/MS</article-title><source>Drug Test Anal</source><year>2020</year><volume>12</volume><issue>9</issue><fpage>1241</fpage><lpage>1251</lpage><pub-id pub-id-type="doi">10.1002/dta.2871</pub-id><pub-id pub-id-type="pmid">32497396</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Pawar RS, Sagi S, Leontyev D (2020) Analysis of bitter orange dietary supplements for natural and synthetic phenethylamines by LC-MS/MS. Drug Test Anal 12(9):1241&#8211;1251. 10.1002/dta.2871<pub-id pub-id-type="pmid">32497396</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/dta.2871</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR51"><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peters</surname><given-names>SA</given-names></name><name name-style="western"><surname>Hultin</surname><given-names>L</given-names></name></person-group><article-title>Early identification of drug-induced impairment of gastric emptying through physiologically based pharmacokinetic (PBPK) simulation of plasma concentration-time profiles in rat</article-title><source>J Pharmacokinet Pharmacodyn</source><year>2008</year><volume>35</volume><issue>1</issue><fpage>1</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1007/s10928-007-9073-1</pub-id><pub-id pub-id-type="pmid">17963025</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Peters SA, Hultin L (2008) Early identification of drug-induced impairment of gastric emptying through physiologically based pharmacokinetic (PBPK) simulation of plasma concentration-time profiles in rat. J Pharmacokinet Pharmacodyn 35(1):1&#8211;30. 10.1007/s10928-007-9073-1<pub-id pub-id-type="pmid">17963025</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10928-007-9073-1</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR52"><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pinckaers</surname><given-names>NET</given-names></name><name name-style="western"><surname>Blankesteijn</surname><given-names>WM</given-names></name><name name-style="western"><surname>Mircheva</surname><given-names>A</given-names></name><etal/></person-group><article-title>In vitro activation of human adrenergic receptors and trace amine-associated receptor 1 by phenethylamine analogues present in food supplements</article-title><source>Nutrients</source><year>2024</year><volume>16</volume><issue>11</issue><fpage>1567</fpage><pub-id pub-id-type="doi">10.3390/nu16111567</pub-id><pub-id pub-id-type="pmid">38892500</pub-id><pub-id pub-id-type="pmcid">PMC11174489</pub-id></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Pinckaers NET, Blankesteijn WM, Mircheva A et al (2024) In vitro activation of human adrenergic receptors and trace amine-associated receptor 1 by phenethylamine analogues present in food supplements. Nutrients 16(11):1567<pub-id pub-id-type="pmid">38892500</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/nu16111567</pub-id><pub-id pub-id-type="pmcid">PMC11174489</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR53"><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Punt</surname><given-names>A</given-names></name><name name-style="western"><surname>Louisse</surname><given-names>J</given-names></name><name name-style="western"><surname>Pinckaers</surname><given-names>N</given-names></name><name name-style="western"><surname>Fabian</surname><given-names>E</given-names></name><name name-style="western"><surname>van Ravenzwaay</surname><given-names>B</given-names></name></person-group><article-title>Predictive Performance of Next Generation Physiologically Based Kinetic (PBK) model predictions in rats based on in vitro and in silico input data</article-title><source>Toxicol Sci</source><year>2021</year><volume>186</volume><issue>1</issue><fpage>18</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1093/toxsci/kfab150</pub-id><pub-id pub-id-type="pmcid">PMC8883350</pub-id><pub-id pub-id-type="pmid">34927682</pub-id></element-citation><mixed-citation id="mc-CR53" publication-type="journal">Punt A, Louisse J, Pinckaers N, Fabian E, van Ravenzwaay B (2021a) Predictive Performance of Next Generation Physiologically Based Kinetic (PBK) model predictions in rats based on in vitro and in silico input data. Toxicol Sci 186(1):18&#8211;28. 10.1093/toxsci/kfab150<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/toxsci/kfab150</pub-id><pub-id pub-id-type="pmcid">PMC8883350</pub-id><pub-id pub-id-type="pmid">34927682</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR54"><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Punt</surname><given-names>A</given-names></name><name name-style="western"><surname>Pinckaers</surname><given-names>N</given-names></name><name name-style="western"><surname>Peijnenburg</surname><given-names>A</given-names></name><name name-style="western"><surname>Louisse</surname><given-names>J</given-names></name></person-group><article-title>Development of a web-based toolbox to support Quantitative In-Vitro-to-In-Vivo Extrapolations (QIVIVE) within nonanimal testing strategies</article-title><source>Chem Res Toxicol</source><year>2021</year><volume>34</volume><issue>2</issue><fpage>460</fpage><lpage>472</lpage><pub-id pub-id-type="doi">10.1021/acs.chemrestox.0c00307</pub-id><pub-id pub-id-type="pmid">33382582</pub-id><pub-id pub-id-type="pmcid">PMC7887804</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Punt A, Pinckaers N, Peijnenburg A, Louisse J (2021b) Development of a web-based toolbox to support Quantitative In-Vitro-to-In-Vivo Extrapolations (QIVIVE) within nonanimal testing strategies. Chem Res Toxicol 34(2):460&#8211;472. 10.1021/acs.chemrestox.0c00307<pub-id pub-id-type="pmid">33382582</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.chemrestox.0c00307</pub-id><pub-id pub-id-type="pmcid">PMC7887804</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR55"><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Punt</surname><given-names>A</given-names></name><name name-style="western"><surname>Louisse</surname><given-names>J</given-names></name><name name-style="western"><surname>Beekmann</surname><given-names>K</given-names></name><etal/></person-group><article-title>Predictive performance of next generation human physiologically based kinetic (PBK) models based on in vitro and in silico input data</article-title><source>Altex</source><year>2022</year><volume>39</volume><issue>2</issue><fpage>221</fpage><lpage>234</lpage><pub-id pub-id-type="pmid">35064272</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.14573/altex.2108301</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Punt A, Louisse J, Beekmann K et al (2022) Predictive performance of next generation human physiologically based kinetic (PBK) models based on in vitro and in silico input data. Altex 39(2):221&#8211;234<pub-id pub-id-type="pmid">35064272</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.14573/altex.2108301</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR56"><mixed-citation publication-type="other">Rafehi M, Faltraco F, Matthaei J, et al. (2019) Highly Variable Pharmacokinetics of Tyramine in Humans and Polymorphisms in OCT1, CYP2D6, and MAO-A. Frontiers in Pharmacology 10 10.3389/fphar.2019.01297<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2019.01297</pub-id><pub-id pub-id-type="pmcid">PMC6831736</pub-id><pub-id pub-id-type="pmid">31736764</pub-id></mixed-citation></ref><ref id="CR57"><mixed-citation publication-type="other">Razenberg L, Notenboom S, De Wit-Bos L (2021) Het gebruik van workout-supplementen door sporters in Nederland. vol 0116,</mixed-citation></ref><ref id="CR58"><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rickli</surname><given-names>A</given-names></name><name name-style="western"><surname>Hoener</surname><given-names>MC</given-names></name><name name-style="western"><surname>Liechti</surname><given-names>ME</given-names></name></person-group><article-title>Pharmacological profiles of compounds in preworkout supplements ("boosters")</article-title><source>Eur J Pharmacol</source><year>2019</year><volume>859</volume><fpage>172515</fpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2019.172515</pub-id><pub-id pub-id-type="pmid">31265842</pub-id></element-citation><mixed-citation id="mc-CR58" publication-type="journal">Rickli A, Hoener MC, Liechti ME (2019) Pharmacological profiles of compounds in preworkout supplements (&#8220;boosters&#8221;). Eur J Pharmacol 859:172515. 10.1016/j.ejphar.2019.172515<pub-id pub-id-type="pmid">31265842</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejphar.2019.172515</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR59"><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodgers</surname><given-names>T</given-names></name><name name-style="western"><surname>Rowland</surname><given-names>M</given-names></name></person-group><article-title>Physiologically based pharmacokinetic modelling 2: Predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions</article-title><source>J Pharm Sci</source><year>2006</year><volume>95</volume><issue>6</issue><fpage>1238</fpage><lpage>1257</lpage><pub-id pub-id-type="doi">10.1002/jps.20502</pub-id><pub-id pub-id-type="pmid">16639716</pub-id></element-citation><mixed-citation id="mc-CR59" publication-type="journal">Rodgers T, Rowland M (2006) Physiologically based pharmacokinetic modelling 2: Predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci 95(6):1238&#8211;1257. 10.1002/jps.20502<pub-id pub-id-type="pmid">16639716</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jps.20502</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR60"><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Skolnik</surname><given-names>S</given-names></name><name name-style="western"><surname>Lin</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X-H</given-names></name><name name-style="western"><surname>He</surname><given-names>T</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B</given-names></name></person-group><article-title>Towards prediction of in vivo intestinal absorption using a 96-well caco-2 assay</article-title><source>J Pharm Sci</source><year>2010</year><volume>99</volume><issue>7</issue><fpage>3246</fpage><lpage>3265</lpage><pub-id pub-id-type="doi">10.1002/jps.22080</pub-id><pub-id pub-id-type="pmid">20166204</pub-id></element-citation><mixed-citation id="mc-CR60" publication-type="journal">Skolnik S, Lin X, Wang J, Chen X-H, He T, Zhang B (2010) Towards prediction of in vivo intestinal absorption using a 96-well caco-2 assay. J Pharm Sci 99(7):3246&#8211;3265. 10.1002/jps.22080<pub-id pub-id-type="pmid">20166204</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jps.22080</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR61"><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>TB</given-names></name><name name-style="western"><surname>Staub</surname><given-names>BA</given-names></name><name name-style="western"><surname>Natarajan</surname><given-names>GM</given-names></name><name name-style="western"><surname>Lasorda</surname><given-names>DM</given-names></name><name name-style="western"><surname>Poornima</surname><given-names>IG</given-names></name></person-group><article-title>Acute myocardial infarction associated with dietary supplements containing 1,3-dimethylamylamine and Citrus aurantium</article-title><source>Tex Heart Inst J</source><year>2014</year><volume>41</volume><issue>1</issue><fpage>70</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.14503/thij-12-2870</pub-id><pub-id pub-id-type="pmid">24512406</pub-id><pub-id pub-id-type="pmcid">PMC3967491</pub-id></element-citation><mixed-citation id="mc-CR61" publication-type="journal">Smith TB, Staub BA, Natarajan GM, Lasorda DM, Poornima IG (2014) Acute myocardial infarction associated with dietary supplements containing 1,3-dimethylamylamine and Citrus aurantium. Tex Heart Inst J 41(1):70&#8211;72. 10.14503/thij-12-2870<pub-id pub-id-type="pmid">24512406</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.14503/THIJ-12-2870</pub-id><pub-id pub-id-type="pmcid">PMC3967491</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR62"><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>D</given-names></name><name name-style="western"><surname>Lennernas</surname><given-names>H</given-names></name><name name-style="western"><surname>Welage</surname><given-names>LS</given-names></name><etal/></person-group><article-title>Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs</article-title><source>Pharm Res</source><year>2002</year><volume>19</volume><issue>10</issue><fpage>1400</fpage><lpage>1416</lpage><pub-id pub-id-type="doi">10.1023/a:1020483911355</pub-id><pub-id pub-id-type="pmid">12425456</pub-id></element-citation><mixed-citation id="mc-CR62" publication-type="journal">Sun D, Lennernas H, Welage LS et al (2002) Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs. Pharm Res 19(10):1400&#8211;1416. 10.1023/a:1020483911355<pub-id pub-id-type="pmid">12425456</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1023/a:1020483911355</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR63"><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suzuki</surname><given-names>O</given-names></name><name name-style="western"><surname>Matsumoto</surname><given-names>T</given-names></name><name name-style="western"><surname>Oya</surname><given-names>M</given-names></name><name name-style="western"><surname>Katsumata</surname><given-names>Y</given-names></name></person-group><article-title>Oxidation of synephrine by type A and type B monoamine oxidase</article-title><source>Experientia</source><year>1979</year><volume>35</volume><issue>10</issue><fpage>1283</fpage><lpage>1284</lpage><pub-id pub-id-type="doi">10.1007/BF01963957</pub-id><pub-id pub-id-type="pmid">499398</pub-id></element-citation><mixed-citation id="mc-CR63" publication-type="journal">Suzuki O, Matsumoto T, Oya M, Katsumata Y (1979) Oxidation of synephrine by type A and type B monoamine oxidase. Experientia 35(10):1283&#8211;1284. 10.1007/BF01963957<pub-id pub-id-type="pmid">499398</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF01963957</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR64"><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Teksin</surname><given-names>ZS</given-names></name><name name-style="western"><surname>Seo</surname><given-names>PR</given-names></name><name name-style="western"><surname>Polli</surname><given-names>JE</given-names></name></person-group><article-title>Comparison of drug permeabilities and BCS classification: three lipid-component PAMPA system method versus Caco-2 monolayers</article-title><source>Aaps j</source><year>2010</year><volume>12</volume><issue>2</issue><fpage>238</fpage><lpage>241</lpage><pub-id pub-id-type="doi">10.1208/s12248-010-9176-2</pub-id><pub-id pub-id-type="pmid">20224985</pub-id><pub-id pub-id-type="pmcid">PMC2844511</pub-id></element-citation><mixed-citation id="mc-CR64" publication-type="journal">Teksin ZS, Seo PR, Polli JE (2010) Comparison of drug permeabilities and BCS classification: three lipid-component PAMPA system method versus Caco-2 monolayers. Aaps j 12(2):238&#8211;241. 10.1208/s12248-010-9176-2<pub-id pub-id-type="pmid">20224985</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1208/s12248-010-9176-2</pub-id><pub-id pub-id-type="pmcid">PMC2844511</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR65"><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vaithianathan</surname><given-names>S</given-names></name><name name-style="western"><surname>Raman</surname><given-names>S</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>W</given-names></name><name name-style="western"><surname>Ting</surname><given-names>TY</given-names></name><name name-style="western"><surname>Kane</surname><given-names>MA</given-names></name><name name-style="western"><surname>Polli</surname><given-names>JE</given-names></name></person-group><article-title>Biopharmaceutic risk assessment of brand and generic lamotrigine tablets</article-title><source>Mol Pharm</source><year>2015</year><volume>12</volume><issue>7</issue><fpage>2436</fpage><lpage>2443</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.5b00154</pub-id><pub-id pub-id-type="pmid">26001027</pub-id></element-citation><mixed-citation id="mc-CR65" publication-type="journal">Vaithianathan S, Raman S, Jiang W, Ting TY, Kane MA, Polli JE (2015) Biopharmaceutic risk assessment of brand and generic lamotrigine tablets. Mol Pharm 12(7):2436&#8211;2443. 10.1021/acs.molpharmaceut.5b00154<pub-id pub-id-type="pmid">26001027</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.molpharmaceut.5b00154</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR66"><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Viana</surname><given-names>C</given-names></name><name name-style="western"><surname>Zemolin</surname><given-names>GM</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>LS</given-names></name><name name-style="western"><surname>Dal Molin</surname><given-names>TR</given-names></name><name name-style="western"><surname>Seiffert</surname><given-names>H</given-names></name><name name-style="western"><surname>de Carvalho</surname><given-names>LM</given-names></name></person-group><article-title>Liquid chromatographic determination of caffeine and adrenergic stimulants in food supplements sold in Brazilian e-commerce for weight loss and physical fitness</article-title><source>Food Addit Contam Part A Chem Anal Control Expo Risk Assess</source><year>2016</year><volume>33</volume><issue>1</issue><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1080/19440049.2015.1112040</pub-id><pub-id pub-id-type="pmid">26560757</pub-id></element-citation><mixed-citation id="mc-CR66" publication-type="journal">Viana C, Zemolin GM, M&#252;ller LS, Dal Molin TR, Seiffert H, de Carvalho LM (2016) Liquid chromatographic determination of caffeine and adrenergic stimulants in food supplements sold in Brazilian e-commerce for weight loss and physical fitness. Food Addit Contam Part A Chem Anal Control Expo Risk Assess 33(1):1&#8211;9. 10.1080/19440049.2015.1112040<pub-id pub-id-type="pmid">26560757</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/19440049.2015.1112040</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR67"><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vieira-Coelho</surname><given-names>MA</given-names></name><name name-style="western"><surname>Teixeira</surname><given-names>VL</given-names></name><name name-style="western"><surname>Guimar&#227;es</surname><given-names>JT</given-names></name><name name-style="western"><surname>Serr&#227;o</surname><given-names>MP</given-names></name><name name-style="western"><surname>Soares-da-Silva</surname><given-names>P</given-names></name></person-group><article-title>Caco-2 cells in culture synthesize and degrade dopamine and 5-hydroxytryptamine: a comparison with rat jejunal epithelial cells</article-title><source>Life Sci</source><year>1999</year><volume>64</volume><issue>1</issue><fpage>69</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1016/s0024-3205(98)00535-9</pub-id><pub-id pub-id-type="pmid">10027744</pub-id></element-citation><mixed-citation id="mc-CR67" publication-type="journal">Vieira-Coelho MA, Teixeira VL, Guimar&#227;es JT, Serr&#227;o MP, Soares-da-Silva P (1999) Caco-2 cells in culture synthesize and degrade dopamine and 5-hydroxytryptamine: a comparison with rat jejunal epithelial cells. Life Sci 64(1):69&#8211;81. 10.1016/s0024-3205(98)00535-9<pub-id pub-id-type="pmid">10027744</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0024-3205(98)00535-9</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR68"><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wardenaar</surname><given-names>FC</given-names></name><name name-style="western"><surname>Ceelen</surname><given-names>IJM</given-names></name><name name-style="western"><surname>Van den Dool</surname><given-names>R</given-names></name><name name-style="western"><surname>Witkamp</surname><given-names>R</given-names></name><name name-style="western"><surname>Mensink</surname><given-names>M</given-names></name></person-group><article-title>Het gebruik van voedingssupplementen en sportvoeding door meer en minder actieve Nederlanders &#8211; Een inventarisatie op basis van het Nationaal Sport Onderzoek 2012 onder de Nederlandse bevolking</article-title><source>Nederlands Tijdschrift Voor Voeding En Dietiek</source><year>2014</year><volume>69</volume><issue>6</issue><fpage>9</fpage></element-citation><mixed-citation id="mc-CR68" publication-type="journal">Wardenaar FC, Ceelen IJM, Van den Dool R, Witkamp R, Mensink M (2014) Het gebruik van voedingssupplementen en sportvoeding door meer en minder actieve Nederlanders &#8211; Een inventarisatie op basis van het Nationaal Sport Onderzoek 2012 onder de Nederlandse bevolking. Nederlands Tijdschrift Voor Voeding En Dietiek 69(6):9</mixed-citation></citation-alternatives></ref><ref id="CR69"><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Faustino</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Volpe</surname><given-names>DA</given-names></name><name name-style="western"><surname>Ellison</surname><given-names>CD</given-names></name><name name-style="western"><surname>Lyon</surname><given-names>RC</given-names></name><name name-style="western"><surname>Yu</surname><given-names>LX</given-names></name></person-group><article-title>Biopharmaceutics classification of selected &#946;-blockers: solubility and permeability class membership</article-title><source>Mol Pharm</source><year>2007</year><volume>4</volume><issue>4</issue><fpage>608</fpage><lpage>614</lpage><pub-id pub-id-type="doi">10.1021/mp070028i</pub-id><pub-id pub-id-type="pmid">17637014</pub-id></element-citation><mixed-citation id="mc-CR69" publication-type="journal">Yang Y, Faustino PJ, Volpe DA, Ellison CD, Lyon RC, Yu LX (2007) Biopharmaceutics classification of selected &#946;-blockers: solubility and permeability class membership. Mol Pharm 4(4):608&#8211;614. 10.1021/mp070028i<pub-id pub-id-type="pmid">17637014</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/mp070028i</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR70"><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yazdanian</surname><given-names>M</given-names></name><name name-style="western"><surname>Glynn</surname><given-names>SL</given-names></name><name name-style="western"><surname>Wright</surname><given-names>JL</given-names></name><name name-style="western"><surname>Hawi</surname><given-names>A</given-names></name></person-group><article-title>Correlating partitioning and caco-2 cell permeability of structurally diverse small molecular weight compounds</article-title><source>Pharm Res</source><year>1998</year><volume>15</volume><issue>9</issue><fpage>1490</fpage><lpage>1494</lpage><pub-id pub-id-type="doi">10.1023/A:1011930411574</pub-id><pub-id pub-id-type="pmid">9755906</pub-id></element-citation><mixed-citation id="mc-CR70" publication-type="journal">Yazdanian M, Glynn SL, Wright JL, Hawi A (1998) Correlating partitioning and caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res 15(9):1490&#8211;1494. 10.1023/A:1011930411574<pub-id pub-id-type="pmid">9755906</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1023/a:1011930411574</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR71"><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>LX</given-names></name><name name-style="western"><surname>Amidon</surname><given-names>GL</given-names></name></person-group><article-title>A compartmental absorption and transit model for estimating oral drug absorption</article-title><source>Int J Pharm</source><year>1999</year><volume>186</volume><issue>2</issue><fpage>119</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.1016/S0378-5173(99)00147-7</pub-id><pub-id pub-id-type="pmid">10486429</pub-id></element-citation><mixed-citation id="mc-CR71" publication-type="journal">Yu LX, Amidon GL (1999) A compartmental absorption and transit model for estimating oral drug absorption. Int J Pharm 186(2):119&#8211;125. 10.1016/S0378-5173(99)00147-7<pub-id pub-id-type="pmid">10486429</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0378-5173(99)00147-7</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR72"><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>C</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>L</given-names></name><name name-style="western"><surname>Chen</surname><given-names>T-M</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>K-K</given-names></name></person-group><article-title>A comparative study of artificial membrane permeability assay for high throughput profiling of drug absorption potential</article-title><source>Eur J Med Chem</source><year>2002</year><volume>37</volume><issue>5</issue><fpage>399</fpage><lpage>407</lpage><pub-id pub-id-type="doi">10.1016/s0223-5234(02)01360-0</pub-id><pub-id pub-id-type="pmid">12008054</pub-id></element-citation><mixed-citation id="mc-CR72" publication-type="journal">Zhu C, Jiang L, Chen T-M, Hwang K-K (2002) A comparative study of artificial membrane permeability assay for high throughput profiling of drug absorption potential. Eur J Med Chem 37(5):399&#8211;407. 10.1016/s0223-5234(02)01360-0<pub-id pub-id-type="pmid">12008054</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0223-5234(02)01360-0</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article></pmc-articleset>